Ala. Code § 20-2-190.2 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-190.2
Section 20-2-190.2 Electronic Drug Offender Tracking System
Status: in_force

(a) For the purposes of this section, the following words shall have the following meanings:

(1) DRUG RELATED CONVICTION. Any conviction or plea of nolo contendere for the offense of possession, distribution, trafficking, or any degree of manufacture of controlled substances, or drug paraphernalia. A drug related conviction shall also include the inchoate crimes of attempt, solicitation, or conspiracy of any of the drug related crimes.

(2) DRUG OFFENDER. Any person who has any conviction listed in subdivision (1).

(b) Effective January 1, 2013, the State Bureau of Investigations shall implement a real-time electronic drug offender tracking system to catalogue all criminal convictions in this state of persons convicted of felonies or misdemeanors involving the possession, distribution, manufacture, or trafficking of controlled substances. This catalogue shall include, but not be limited to, paraphernalia convictions, violations of this article, in whole or in part, attempts, conspiracies, or solicitations to commit any crime involving the possession, distribution, or manufacture of controlled substances. A drug offender convicted of violations of Act 2012-237, possession of a controlled substance, or drug paraphernalia shall remain in the drug offender tracking system for seven years beginning upon each conviction. A drug offender convicted of manufacture, distribution, or trafficking of controlled substances shall remain in the drug offender tracking system for ten years beginning upon each conviction. A person’s name shall be removed from the tracking system upon the expiration of the applicable seven or ten years from the adjudication or conviction of the last violation and confirmation that the drug offender has no new convictions.

(c) The electronic drug offender tracking system shall have the technological capability to receive ephedrine and pseudoephedrine sales data from pharmacies submitted pursuant to this section. The electronic drug offender tracking system shall be capable of bridging with existing and future operational systems used by pharmacies at no charge to the pharmacies. The State Bureau of Investigations may enter into a public-private partnership, through a memorandum of understanding or similar arrangement, to make the system available to pharmacies and law enforcement in the state.

(d)(1) Effective January 1, 2013, the State Bureau of Investigations, in cooperation with the National Association of Drug Diversion Investigators, which administers the National Precursor Log Exchange, shall devise a method to electronically notify the association at least every seven days of any person placed on the drug offender tracking system. The notification shall include the first, middle, and last names of the person, as well as the person’s date of birth. The State Bureau of Investigations shall devise a method to issue a stop sale alert for any purchaser whose name has been submitted to the national registry.

(2) The State Bureau of Investigations shall notify the association when a person is removed from the drug offender tracking system as required under subsection (b).

(e) The information contained in this electronic drug offender tracking system shall be available:

(1) To any law enforcement agency or entity as authorized by the State Bureau of Investigations.

(2) Pursuant to a subpoena.

(f) The drug offender tracking system shall be capable of generating a stop sale alert, which shall be a notification that the purchaser has a previous conviction for a drug related offense and completion of the sale would result in a violation of law under Section 20-2-190. The system shall contain an override function for use by a dispenser of ephedrine or pseudoephedrine who has a reasonable fear of imminent bodily harm. Each instance in which the override function is utilized shall be logged by the system.

(g) Effective January 1, 2013, provided a system is available to the state without cost to the state or pharmacies for accessing the system, before completing a sale of a product covered by this section, a pharmacy shall submit the required information to the electronic drug offender tracking system established under subsection (b).

(h) If the pharmacy, after checking the electronic drug offender database, determines the purchaser is a drug offender, the pharmacist shall not complete the sale, except when the seller follows the procedure described under subsection (f) for overriding the stop sale alert when the seller has fear of bodily harm.

(i) Any seller who fails to comply with this section shall be guilty of a Class A misdemeanor for a first offense, and a Class C felony for a second or subsequent offense, except that sellers who exercise the override feature described under section (f) when a stop sale alert is generated shall not be subject to misdemeanor or felony charges. Absent negligence, wantonness, recklessness, or deliberate misconduct, any pharmacist maintaining the electronic drug offender tracking system in accordance with this section shall not be civilly liable as a result of any act or omission in carrying out the duties required by this subsection and shall be immune from liability to any third party unless the pharmacy has violated any provision of this subsection in relation to a claim brought for such violation.

(j)(1) A drug offender convicted of violations of Act 2012-237, possession of a controlled substance, or drug paraphernalia shall be prohibited from the retail or prescription purchase of any ephedrine or pseudoephedrine, their salts or optical isomers, or salts of optical isomers or product for the entire seven years the person is required to be included in the drug offender tracking system.

(2) A drug offender convicted of manufacture, distribution, or trafficking of controlled substances shall be prohibited from the retail or prescription purchase of any ephedrine or pseudoephedrine, their salts or optical isomers, or salts of optical isomers, or product for the entire ten years the person is required to be included in the drug offender tracking system.

(k) A drug offender who knowingly and unlawfully purchases or attempts, solicits another, or conspires to purchase ephedrine or pseudoephedrine, their salts or optical isomers, or salts of optical isomers or product in violation of this section, is guilty of a Class A misdemeanor, except upon a subsequent conviction, is guilty of a Class C felony.
Ala. Code § 20-2A-80 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-80
Section 20-2A-80 Tax on Retail Sales of Medical Cannabis; Annual Medical Cannabis Privilege Tax
Status: in_force

(a) Commencing January 1, 2022, there is levied, in addition to all other taxes of every kind now imposed by law, and shall be collected and remitted in accordance with Article 1, commencing with Section 40-23-1, of Chapter 23 of Title 40, a tax on the gross proceeds of the sales of medical cannabis when sold at retail in this state at the rate of nine percent of the gross proceeds of the sales.

(b)(1) Commencing January 1, 2022, there is levied an annual privilege tax on every person doing business under this chapter in Alabama. The tax shall accrue as of January 1 of every taxable year, or in the case of a taxpayer licensed under this chapter, during the year, or doing business in this state for the first time, as of the date the taxpayer is licensed to do business under this chapter. The tax shall be levied upon the taxpayer’s net worth in Alabama for the taxable year. For purposes of this subdivision, a taxpayer’s net worth in Alabama shall be determined by apportioning the taxpayer’s net worth computed under Section 40-14A-23, in the same manner as prescribed for apportioning income during the determination period for purposes of the income tax levied by Chapter 18 of Title 40, or the manner in which the income would be apportioned if the taxpayer were subject to the income tax.

(2) The amount of tax due shall be computed in the same manner and at the same rate of tax as prescribed in Section 40-14A-22, for purposes of determining the annual privilege tax levied by Chapter 14A of Title 40.

(3) The annual return required by this subsection shall be due no later than the corresponding federal income tax return, as required to be filed under federal law. In the case of a taxpayer’s initial return, the annual return shall be due no later than two and one-half months after the taxpayer is licensed to do business, or commences business, in Alabama.

(4) The Department of Revenue may grant a reasonable extension of time for filing returns under rules adopted by the Department of Revenue. No extension shall be for more than six months.

(5) The annual medical cannabis privilege tax shall be reported on forms and in the manner as prescribed by rule by the Department of Revenue. The failure to receive a form from the Department of Revenue shall not relieve a taxpayer from liability for any tax, penalty, or interest otherwise due. The tax due, as reported, shall constitute an admitted liability for that amount. The Department of Revenue may compute and assess additional tax, penalty, and interest against a taxpayer as provided in this chapter.

(c) The Department of Revenue shall adopt rules to implement this section.
Ala. Code § 20-2-90 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-90
Section 20-2-90 State Board of Pharmacy, Alabama State Law Enforcement Agency, Etc., to Enforce Chapter; Drug Inspectors to Meet Minimum Standards
Status: in_force

(a) The State Board of Pharmacy and its drug investigators shall enforce this chapter. The agents and officers of the Alabama State Law Enforcement Agency, the drug and narcotic agents and inspectors of the State Board of Health, the investigators of the State Board of Medical Examiners, the investigators of the Board of Dental Examiners, and all peace officers of the state and all prosecuting attorneys are also charged with the enforcement of this chapter. The agents and officers of the Alabama State Law Enforcement Agency, the drug investigators of the State Board of Pharmacy, the investigators of the State Board of Medical Examiners, the investigators of the Board of Dental Examiners, and the drug and narcotic agents and inspectors of the State Board of Health shall have the powers of peace officers in the performance of their duties to:

(1) Make arrests without warrant for any offense under this chapter committed in their presence, or if they have probable cause to believe that the person to be arrested has committed or is committing a violation of this chapter which may constitute a felony.

(2) Make seizures of property pursuant to this chapter.

(3) Carry firearms in the performance of their official duties.

(b) In addition to the requirements of subsection (a), drug investigators of the State Board of Pharmacy shall, beginning October 1, 1993, meet the minimum standards required of peace officers in this state.
Ala. Code § 20-2A-31 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-31
Section 20-2A-31 Registered Certifying Physician - Requirements
Status: in_force

(a) In order for a physician to qualify as a registered certifying physician, he or she must meet the following requirements:

(1) Hold an active license to practice medicine under Chapter 24 of Title 34.

(2) Complete a four-hour course related to medical cannabis and complete a subsequent examination, both of which shall be offered by a multi-specialty statewide professional organization of physicians in this state that is recognized to accredit intrastate organizations to provide AMA PRA category 1 credits. The course must be administered at least annually and may be offered in a distance learning format, including an electronic online format upon request. The price of the course may not exceed five hundred dollars ($500). Every two years thereafter, in order to requalify, a certifying physician must complete a two-hour refresher course offered by an entity described in this subdivision.

(3) Pay an initial registration fee established by the board, not to exceed three hundred dollars ($300).

(4) Meet any additional qualifications established by rule by the board.

(b) Upon meeting the requirements of subsection (a), the board shall issue a registration certificate and registration number to each registered certifying physician. The board shall maintain on its website an updated list of registered certifying physicians.

(c) The board, by rule, may establish requirements for registered certifying physicians to remain qualified, grounds for revoking registration, and a process for renewing registration of qualified certifying physicians, including payment of an annual registration renewal fee, not to exceed two hundred dollars ($200).
Ala. Code § 20-2-215 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-215
Section 20-2-215 Confidentiality of Database
Status: in_force

(a) The controlled substances database and all information contained therein and any records maintained by the department or by any entity contracting with the department which is submitted to, maintained, or stored as a part of the controlled substances prescription database, and any reproduction or copy of that information is declared privileged and confidential, is not a public record, and is not subject to subpoena or discovery in civil proceedings. This information is considered clinical in nature, subject to medical interpretation, and may only be used for any of the following:

(1) Investigatory or evidentiary purposes related to violations of state or federal law.

(2) Regulatory activities of licensing or regulatory boards of practitioners authorized to prescribe or dispense controlled substances.

(3) Informing pharmacists and practitioners in prescribing or dispensing controlled substances.

(4) Bona fide statistical, research, or educational purposes when information is properly de-identified as provided in this article.

(b) Nothing in this section shall apply to records not originating from the controlled substances database that are created or maintained in the regular course of business of a pharmacy, medical, dental, optometric, or veterinary practitioner, or other entity covered by this article and all information, documents, or records otherwise available from original sources are not to be construed as immune from discovery or use in any civil proceedings merely because such information contained in those records was reported to the controlled substances prescription database in accordance with the provisions of this article.
Ala. Code § 20-1-1 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-1
Section 20-1-1 Short Title; Enforcement of Chapter
Status: in_force

This chapter may be cited as the “Alabama Safe Foods Act of 2000.”

The Commissioner of Agriculture and Industries, through the facilities of the state Department of Agriculture and Industries, shall enforce the provisions of this chapter. The administrative and enforcement provisions of Title 2 of this code shall, unless inapplicable by their nature, apply to the administration and enforcement of this chapter.
Ala. Code § 20-2-51 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-51
Section 20-2-51 Registration of Persons Manufacturing, Distributing, or Dispensing Controlled Substances - General Requirements
Status: in_force

(a) Every person who manufactures, distributes, or dispenses any controlled substance within this state or who proposes to engage in the manufacture, distribution, or dispensing of any controlled substance within this state must obtain annually a registration issued by the certifying boards in accordance with its rules.

(b) Persons registered by the certifying boards under this chapter to manufacture, distribute, dispense, or conduct research with controlled substances may possess, manufacture, distribute, dispense, or conduct research with those substances to the extent authorized by their registration and in conformity with the other provisions of this article.

(c) The following persons need not register and may lawfully possess controlled substances under this article:

(1) An agent or employee of any registered manufacturer, distributor, or dispenser of any controlled substance if he is acting in the usual course of his business or employment;

(2) A common or contract carrier or warehouseman or an employee thereof whose possession of any controlled substance is in the usual course of business or employment;

(3) An ultimate user or a person in possession of any controlled substance pursuant to a lawful order of a practitioner or in lawful possession of a Schedule V substance.

(d) The certifying boards may waive by rule the requirement for registration of certain manufacturers, distributors, or dispensers if they find it consistent with the public health and safety.

(e) A separate registration is required at each principal place of business or professional practice where the applicant manufactures, distributes, or dispenses controlled substances.

(f) The certifying boards may inspect the establishment of a registrant or applicant for registration in accordance with the rules and regulations promulgated by them.
Ala. Code § 20-2-52 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-52
Section 20-2-52 Registration of Persons Manufacturing, Distributing or Dispensing Controlled Substances - Standards; Requirements as to Practitioners Conducting Research; Effect of Federal Registration
Status: in_force

(a) The certifying boards shall register only an applicant certified by their respective boards to manufacture, dispense, or distribute controlled substances enumerated in Schedules I, II, III, IV and V; provided, that the State Board of Pharmacy shall register all manufacturers and wholesalers unless they determine that the issuance of that registration would be inconsistent with the public interest. In determining the public interest, the above-mentioned boards shall consider the following factors:

(1) Maintenance of effective controls against diversion of controlled substances into other than legitimate medical, scientific, or industrial channels;

(2) Compliance with applicable state and local law;

(3) Any convictions of the applicant under any federal and state laws relating to any controlled substance;

(4) Past experience in the manufacture or distribution of controlled substances and the existence in the applicant’s establishment of effective controls against diversion;

(5) Furnishing by the applicant of false or fraudulent material in any application filed under this article;

(6) Suspension or revocation of the applicant’s federal registration to manufacture, distribute, or dispense controlled substances as authorized by federal law; and

(7) Any other factors relevant to and consistent with the public health and safety.

(b) Registration under subsection (a) of this section does not entitle a registrant to manufacture and distribute controlled substances in Schedule I or II other than those specified in the registration.

(c) Practitioners must be registered to dispense any controlled substances or to conduct research with controlled substances in Schedules II through V if they are authorized to dispense or conduct research under the laws of this state. The State Board of Health need not require separate registration under this article for practitioners engaging in research with nonnarcotic controlled substances in Schedules II through V where the registrant is already registered under this article in another capacity. Practitioners registered under federal law to conduct research with Schedule I substances may conduct research with Schedule I substances within this state upon furnishing the State Board of Health evidence of that federal registration.

(d) Compliance by manufacturers and distributors with the provisions of the federal law respecting registration (excluding fees) entitles them to be registered under this article.
Ala. Code § 20-2-219 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-219
Section 20-2-219 Database Funding
Status: in_force

The department may make deposits into the fund from any source, public or private, including grants or contributions of money or other items of value, which it determines necessary to carry out the purpose of the program. Notwithstanding amounts contained in the fund that remain unencumbered or unobligated at the close of the fiscal year shall not revert but shall remain available for expenditure for the purposes designated in future years.
Ala. Code § 20-1-78 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-78
Section 20-1-78 Powers and Duties of State Board of Agriculture and Industries; Rules and Regulations
Status: in_force

(a) The State Board of Agriculture and Industries, as the administrative agency, shall perform all of the following duties:

(1) To make, amend, and rescind such rules and regulations as may be necessary to carry out the provisions of this article, including, but without being limited to, such orders, rules, and regulations as it is hereinafter specifically authorized and directed to make and to establish fees for reimbursement of expenses.

(2) To adopt from time to time such regulations changing or adding to the required ingredients for flour, cornmeal, grits, or bread specified in Sections 20-1-73 through 20-1-75 as shall be necessary to conform to the definitions and standards of identity of enriched flour and other products from time to time promulgated by the appropriate federal agency pursuant to the federal Food, Drug and Cosmetic Act.

(3) To issue an order, to be effective immediately upon issuance, in the event of the finding by the board that there is an existing shortage of any ingredient required under Sections 20-1-73, 20-1-74, and 20-1-75, with the result that the sale and distribution of this product may be substantially impeded by the enforcement of this article, permitting the omission of such ingredient from this product. Whenever the state board finds that such shortage no longer exists, it shall issue an order, to be effective not less than 10 days after publication thereof, revoking such order. Any such findings as to the existence or imminence of any such shortage or the cessation thereof may be made by the state board without any hearing, on the basis of an order of or factual information supplied by the appropriate federal agency (as defined in subdivision (7) of Section 20-1-71) or any similar federal agency. In the absence of any such order or factual information, the state board, upon receiving the sworn statement of any persons subject to this article that such a shortage exists or is imminent or has ceased, shall, within 10 days thereafter, hold a public hearing with respect thereto, at which time any interested person may present evidence in support of such sworn statement, and any such finding by the state board may be based upon the evidence so presented. The state board shall publish notice of any such hearing at least 10 days prior thereto.

(b) All orders, rules, and regulations adopted by the board pursuant to this article shall be published in the manner prescribed in subsection (c) of this section, and, within the limits specified by this article, shall become effective upon such date as the state board shall fix.

(c) Whenever under this article publication of any notice, order, rule, or regulation is required, the publication shall be made at least three times in 10 days in newspapers of general circulation in three different sections of this state.
Ala. Code § 20-2A-3 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-3
Section 20-2A-3 Definitions
Status: in_force

As used in this chapter, the following terms have the following meanings:

(1) APPLICANT. The entity or individual seeking a license under Article 4.

(2) BOARD. The State Board of Medical Examiners.

(3) CANNABIS. a. Except as provided in paragraph b., all parts of any plant of the genus cannabis, whether growing or not, including the seeds, extractions of any kind from any part of the plant, and every compound, derivative, mixture, product, or preparation of the plant.

b. The term does not include industrial hemp or hemp regulated under Article 11 of Chapter 8 of Title 2.

(4) COMMISSION. The Alabama Medical Cannabis Commission created pursuant to Section 20-2A-20.

(5) CULTIVATOR. An entity licensed by the commission under Section 20-2A-62 authorized to grow cannabis pursuant to Article 4.

(6) DAILY DOSAGE. The total amount of one or more cannabis derivatives, including, but not limited to, cannabidiol and tetrahydrocannabinol, which may be present in a medical cannabis product that may be ingested by a registered qualified patient during a 24-hour period, as determined by a registered certifying physician.

(7) DEPARTMENT. The Department of Agriculture and Industries.

(8) DISPENSARY. An entity licensed by the commission under Section 20-2A-64 authorized to dispense and sell medical cannabis at dispensing sites to registered qualified patients and registered caregivers pursuant to Article 4.

(9) DISPENSING SITE. A site operated by a dispensary licensee or an integrated facility licensee pursuant to Article 4.

(10) ECONOMIC INTEREST. The rights to either the capital or profit interests of an applicant or licensee or, if the applicant or licensee is a corporation, the rights to some portion of all classes of outstanding stock in the corporation.

(11) FACILITY or MEDICAL CANNABIS FACILITY. Any facility, or land associated with a facility, of a licensee.

(12) INTEGRATED FACILITY. An entity licensed under Section 20-2A-67 authorized to perform the functions of a cultivator, processor, secure transporter, and dispensary pursuant to Article 4.

(13) LICENSEE. A cultivator, processor, secure transporter, state testing laboratory, dispensary, or integrated facility licensed by the commission under Article 4.

(14) MEDICAL CANNABIS. a. A medical grade product in the form of any of the following, as determined by rule by the commission, that contains a derivative of cannabis for medical use by a registered qualified patient pursuant to this chapter:

1. Oral tablet, capsule, or tincture.

2. Non-sugarcoated gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or rectangular cuboid shape.

3. Gel, oil, cream, or other topical preparation.

4. Suppository.

5. Transdermal patch.

6. Nebulizer.

7. Liquid or oil for administration using an inhaler.

b. The term does not include any of the following:

1. Raw plant material.

2. Any product administered by smoking, combustion, or vaping.

3. A food product that has medical cannabis baked, mixed, or otherwise infused into the product, such as cookies or candies.

(15) MEDICAL CANNABIS CARD. A valid card issued pursuant to Section 20-2A-36.

(16) MEDICAL USE or USE OF MEDICAL CANNABIS or USE MEDICAL CANNABIS. The acquisition, possession, use, delivery, transfer, or administration of medical cannabis authorized by this chapter. The term does not include possession, use, or administration of cannabis that was not purchased or acquired from a licensed dispensary.

(17) PACKAGE. Any container that a processor may use for enclosing and containing medical cannabis. The term does not include any carry-out bag or other similar container.

(18) PATIENT REGISTRY. The Alabama Medical Cannabis Patient Registry System that is an electronic integrated system that tracks physician certifications, patient registrations, medical cannabis cards, the daily dosage and type of medical cannabis recommended to qualified patients by registered certifying physicians, and the dates of sale, amounts, and types of medical cannabis that were purchased by registered qualified patients at licensed dispensaries.

(19) PHYSICIAN CERTIFICATION. A registered certifying physician’s authorization for a registered qualified patient to use medical cannabis.

(20) PROCESSOR. An entity licensed by the commission under Section 20-2A-63 authorized to purchase cannabis from a cultivator and extract derivatives from the cannabis to produce a medical cannabis product or products for sale and transfer in packaged and labeled form to a dispensing site pursuant to Article 4.

(21) QUALIFYING MEDICAL CONDITION. Any of the following conditions or symptoms of conditions, but only after documentation indicates that conventional medical treatment or therapy has failed unless current medical treatment indicates that use of medical cannabis is the standard of care:

a. Autism Spectrum Disorder (ASD).

b. Cancer-related cachexia, nausea or vomiting, weight loss, or chronic pain.

c. Crohn’s Disease.

d. Depression.

e. Epilepsy or a condition causing seizures.

f. HIV/AIDS-related nausea or weight loss.

g. Panic disorder.

h. Parkinson’s disease.

i. Persistent nausea that is not significantly responsive to traditional treatment, except for nausea related to pregnancy, cannabis-induced cyclical vomiting syndrome, or cannabinoid hyperemesis syndrome.

j. Post Traumatic Stress Disorder (PTSD).

k. Sickle Cell Anemia.

l. Spasticity associated with a motor neuron disease, including Amyotrophic Lateral Sclerosis.

m. Spasticity associated with Multiple Sclerosis or a spinal cord injury.

n. A terminal illness.

o. Tourette’s Syndrome.

p. A condition causing chronic or intractable pain in which conventional therapeutic intervention and opiate therapy is contraindicated or has proved ineffective.

(22) REGISTERED CAREGIVER. An individual who meets the requirements described in subsection (c) of Section 20-2A-30 and is authorized to acquire and possess medical cannabis and to assist one or more registered qualified patients with the use of medical cannabis pursuant to this chapter.

(23) REGISTERED CERTIFYING PHYSICIAN. A physician authorized by the State Board of Medical Examiners to certify patients for the use of medical cannabis under this chapter.

(24) REGISTERED QUALIFIED PATIENT. Either of the following:

a. An adult who meets the requirements described in subsection (a) of Section 20-2A-30 and is authorized to acquire, possess, and use medical cannabis pursuant to this chapter.

b. A minor who meets the requirements described in subsection (b) of Section 20-2A-30 and is authorized to use medical cannabis pursuant to this chapter with the assistance of a registered caregiver.

(25) SECURE TRANSPORTER. An entity licensed by the commission under Section 20-2A-65 authorized to transport cannabis or medical cannabis from one licensed facility or site to another licensed facility or site.

(26) STATE TESTING LABORATORY. An entity licensed under Section 20-2A-66 authorized to test cannabis and medical cannabis to ensure the product meets safety qualifications required under this chapter.

(27) STATEWIDE SEED-TO-SALE TRACKING SYSTEM. The tracking system established pursuant to Section 20-2A-54 that tracks all cannabis and medical cannabis in the state.

(28) UNIVERSAL STATE SYMBOL. The image established by the commission pursuant to Section 20-2A-53 made available to processors which indicates the package contains medical cannabis.
Ala. Code § 20-2B-8 — Alabama Code / Title 20 / Chapter 2B / Section 20-2B-8
Section 20-2B-8 Inventory Provided to Individuals Named in Order or Application; Disclosure of Records
Status: in_force

(a) Within a reasonable time, but not later than 90 days after the date an application for an order is denied or after the date an order, or the last extension, if any, expires, the judge who granted or denied the application shall serve an inventory on the individuals named in the order or the application or any other parties to the intercepted communications deemed appropriate by the issuing judge, if any. The inventory shall include a notice of all of the following:

(1) The entry of the order or the application.

(2) The date of the entry and the period of authorized interception or the date of denial of the application.

(3) Whether wire or electronic communications were intercepted during the authorized period.

(b) Upon a motion, the judge may make available for inspection to any individual or individuals whose communications have been intercepted, or their counsel, any portion of an intercepted communication, application, or order the judge determines is in the interest of justice to disclose to that individual.

(c) Upon an ex parte showing of good cause to the judge, the serving of the inventory required by this section may be postponed, but evidence derived from an order under this chapter may not be disclosed in any trial until after the inventory has been served.
Ala. Code § 20-1-29 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-29
Section 20-1-29 Shipment, Offer for Shipment, or Sale of Certain Citrus Fruits
Status: reserved

Repealed by Act 2015-70 effective April 21, 2015.
Ala. Code § 20-2-217 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-217
Section 20-2-217 Surcharge on Controlled Substance Registration Certificate
Status: in_force

There is hereby assessed a surcharge in the amount of ten dollars ($10) per year on the controlled substance registration certificate of each licensed medical, dental, podiatric, optometric, and veterinary medicine practitioner authorized to prescribe or dispense controlled substances and on the Qualified Alabama Controlled Substances Registration Certificate (QACSC) of each licensed assistant to physician, certified registered nurse practitioner, or certified nurse midwife. This surcharge shall be effective for every practitioner certificate and every Qualified Alabama Controlled Substances Registration Certificate (QACSC) issued or renewed, shall be in addition to any other fees collected by the certifying boards, and shall be collected by each of the certifying boards and remitted to the department at such times and in such manner as designated in the regulations of the department. The proceeds of the surcharge assessed herein shall be used exclusively for the development, implementation, operation, and maintenance of the controlled substances prescription database.
Ala. Code § 20-2A-62 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-62
Section 20-2A-62 Cultivator Licensing
Status: in_force

AMENDED BY ACT 2024-342, EFFECTIVE JUNE 1, 2024. SEE VERSION LABELED PENDING.

(a)(1) A cultivator license authorizes all of the following:

a. The cultivation of cannabis.

b. The sale or transfer of cannabis to a processor.

c. If the cultivator contracts with a processor to process its cannabis into medical cannabis on the cultivator’s behalf, the sale or transfer of medical cannabis to a dispensary.

(2) A cultivator license authorizes the cultivator to transfer cannabis only by means of a secure transporter.

(b) The commission shall consult with the Department of Agriculture and Industries when determining the number of cultivator licenses to issue, provided the commission shall issue no more than 12 cultivator licenses.

(c) An applicant for a license under this section shall meet all of the following requirements:

(1) Demonstrate the ability to secure and maintain cultivation facilities.

(2) Demonstrate the ability to obtain and use an inventory control and tracking system as required under Section 20-2A-60.

(3) Demonstrate the ability to commence cultivation of cannabis within 60 days of application approval notification.

(4) Demonstrate the ability to destroy unused or waste cannabis in accordance with rules adopted by the department.

(5) Demonstrate the financial stability to provide proper testing of individual lots and batches.

(d) A licensed cultivator shall comply with all of the following, in accordance with rules adopted by the department:

(1) All facilities shall be protected by a monitored security alarm system, be enclosed, and remain locked at all times.

(2) All individuals entering and exiting facilities shall be monitored by video surveillance and keypad or access card entry.

(3) All employees may not have any conviction within the past 10 years for a controlled substance-related felony or a controlled substance-related misdemeanor other than a conviction that was overturned on appeal or a charge that was expunged pursuant to Chapter 27 of Title 15.

(4) Cultivars selected by a licensee must be approved by the department prior to acquisition of plant material for cultivation.

(e) A cultivator shall be subject to inspection by the department.

(f) The cultivation of cannabis pursuant to this chapter shall be considered an agricultural purpose for purposes of Section 40-23-4.

(g) Nothing in this section shall be construed to prohibit the hydroponic growing of cannabis.

(h) The department shall consult with the commission when adopting rules pursuant to this article.
Ala. Code § 20-2-64 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-64
Section 20-2-64 Denial of Application
Status: in_force

The board may deny an application of an assistant to physician requesting a Qualified Alabama Controlled Substances Registration Certificate, deny a request for a renewal of a QACSC, or initiate disciplinary action against an assistant to physician possessing a Qualified Alabama Controlled Substances Registration Certificate based on the following grounds:

(1) Fraud or deceit in applying for, procuring, or attempting to procure a Qualified Alabama Controlled Substances Registration Certificate in the State of Alabama.

(2) Conviction of a crime under any state or federal law relating to any controlled substance.

(3) Conviction of a crime or offense which affects the ability of the assistant to physician to practice with due regard for the health or safety of his or her patients.

(4) Prescribing a drug or utilizing a Qualified Alabama Controlled Substances Registration Certificate in such a manner as to endanger the health of any person or patient of the assistant to physician or supervising physician.

(5) Suspension or revocation of the registration number issued to the assistant to physician by the United States Drug Enforcement Administration.

(6) Excessive dispensing or prescribing of any drug to any person or patient of the assistant to physician or supervising physician.

(7) Unfitness or incompetence due to the use of or dependence on alcohol, chemicals, or any mood altering drug to such an extent as to render the assistant to physician unsafe or unreliable to prescribe drugs or to hold a Qualified Alabama Controlled Substances Registration Certificate.

(8) Any violation of a requirement set forth in this article or a rule adopted pursuant to this article.
Ala. Code § 20-2-78 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-78
Section 20-2-78 Penalties Imposed for Violations of Chapter in Addition to Other Civil or Administrative Penalties or Sanctions
Status: in_force

Any penalty imposed for violation of this chapter is in addition to and not in lieu of any civil or administrative penalty or sanction otherwise authorized by law.
Ala. Code § 20-2-113 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-113
Section 20-2-113 Controlled Substances Therapeutic Research Program - Established; Review Committee; Rules and Regulations; Formulation with Federal Agencies
Status: in_force

There is hereby established by the State Board of Medical Examiners the Controlled Substances Therapeutic Research Program. The board shall administer the program by a review committee. The board shall promulgate such rules and regulations as are necessary for the proper administration and implementation of the program. Such promulgations shall be formulated to consider those pertinent rules and regulations promulgated by the Federal Drug Enforcement Agency, Food and Drug Administration and the National Institute on Drug Abuse.
Ala. Code § 20-2-190.1 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-190.1
Section 20-2-190.1 Legislative Intent
Status: in_force

(a) The Legislature finds the following:

(1) The danger of methamphetamine manufacture to the public and especially to law enforcement involved in the investigation and clean-up of clandestine methamphetamine laboratories is of paramount concern.

(2) Ephedrine or pseudoephedrine, their salts or optical isomers, or salts of optical isomers are the essential ingredient in the manufacture of methamphetamine.

(b) It is the intent of the Legislature to prevent and criminally sanction the practice of smurfing. Smurfing is the common name for the act of a person within the state or from other states, acting alone or in concert, at the direction or behest of another to circumvent the provisions of state law by purchasing multiple quantities of pseudoephedrine and ephedrine compounds for the intent of combining or using such quantities for the purposes of manufacturing or attempting to manufacture methamphetamine.
Ala. Code § 20-2B-13 — Alabama Code / Title 20 / Chapter 2B / Section 20-2B-13
Section 20-2B-13 Violations of Article
Status: in_force

Any individual who knowingly and intentionally possesses, installs, operates, or monitors an electronic, mechanical, or other device in violation of this chapter shall be guilty of a Class C felony.
Ala. Code § 20-2-180 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-180
Section 20-2-180 Definitions
Status: in_force

As used in this article and unless otherwise specified, the following terms are defined as follows:

(1) BOARD or BOARD OF PHARMACY. The Alabama State Board of Pharmacy.

(2) LISTED PRECURSOR CHEMICAL. A chemical substance specifically designated as such by the Alabama State Board of Pharmacy, that, in addition to legitimate uses, is used in the unlawful manufacture of a controlled substance or controlled substances.

(3) PERSON. Any individual, corporation, partnership, association, or other entity which manufactures, sells, transfers, or possesses a listed precursor chemical.
Ala. Code § 20-1-153 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-153
Section 20-1-153 Exemptions from Imprinting Requirement
Status: in_force

The State Board of Health may exempt drug products from the requirements of Section 20-1-150 on the grounds that imprinting is not feasible because of size, texture, or other unique characteristics.
Ala. Code § 20-2A-33 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-33
Section 20-2A-33 Physician Certifications of Patients; Rulemaking Authority; Patient Registry Information
Status: in_force

(a) In order to certify a patient, a registered certifying physician must diagnose the patient with at least one qualifying medical condition or confirm that the patient has been medically diagnosed with at least one qualifying medical condition.

(b) Not later than December 1, 2021, the board shall adopt rules for the issuance of physician certifications for patients to use medical cannabis as recommended by a registered certifying physician. The rules shall include, but not be limited to, all of the following:

(1) Requirements for patient examination and the establishment of a physician-patient relationship.

(2) Requirements for relevant information to be included in the patient’s medical record.

(3) Requirements for review of the patient’s controlled drug prescription history in the controlled substance prescription database established under Article 10 of Chapter 2 of this title.

(4) Requirements for review of the patient registry.

(5) Requirements for obtaining the voluntary and informed written consent from the patient to use medical cannabis, or from the patient’s designated caregiver to assist the patient with the use of medical cannabis, on a form created by the board and accessible at no charge on its website. The form shall include, but not be limited to, information relating to all of the following:

a. The federal and state classification of cannabis as a Schedule I controlled substance.

b. The approval and oversight status of cannabis by the Food and Drug Administration.

c. The current state of research on the efficacy of cannabis to treat the qualifying medical condition or conditions.

d. The potential for addiction.

e. The potential effect that cannabis may have on a patient’s coordination, motor skills, and cognition, including a warning against operating heavy machinery, operating a motor vehicle, or engaging in activities that require an individual to be alert or respond quickly.

f. The potential side effects of cannabis use.

g. The risks, benefits, and drug interactions of cannabis.

h. A statement that the use of medical cannabis could result in termination from employment without recourse and that costs may not be covered by insurance or government programs.

i. That the patient’s de-identified health information contained in the patient’s medical record, physician certification, and patient registry may be used for research purposes or used to monitor compliance with this chapter, as further provided in subsection (c) of Section 20-2A-35.

(6) Requirements for the issuance and reissuance of physician certifications by certifying physicians, the permissible length of duration of a physician certification, and the process and circumstances under which a physician certification may be deactivated, as well as stipulations for timely updating of physician certifications on the patient registry.

(c) At the time of physician certification, the registered certifying physician shall enter electronically in the patient registry, in a manner determined by rule by the board, relevant information necessary to appropriately identify the patient; the respective qualifying medical condition or conditions of the patient; the daily dosage and type of medical cannabis recommended for medical use; and any other information the board, by rule, deems relevant.

(d) A physician certification does not constitute a prescription for medical cannabis.

(e) A physician certification shall be valid for a period of time as determined by the board, but in no event may a physician certification exceed 12 months in duration.

(f)(1) The commission, by rule, shall specify, by form and tetrahydrocannabinol content, a maximum daily dosage of medical cannabis that may be recommended by a registered certifying physician for a particular qualifying medical condition, which may not exceed the limits set forth in subdivision (2).

(2) The maximum daily dosage may not exceed 50 mg of delta-9-tetrahydrocannabinol; provided, however, the maximum daily dosage may be increased under either of the following circumstances:

a. A registered certifying physician may increase a patient’s daily dosage if, after 90 days of continuous care under the physician during which time the patient was using medical cannabis, the physician determines that a higher daily dosage is medically appropriate, provided the maximum daily dosage under this paragraph may not exceed 75 mg of delta-9-tetrahydrocannabinol.

b. A registered certifying physician may increase a patient’s daily dosage if the patient has been diagnosed with a terminal illness, provided, if the recommended daily dosage exceeds 75 mg of delta-9-tetrahydrocannabinol, the physician shall notify the patient that the patient’s driver’s license will be suspended.

(g) A registered certifying physician may not lawfully recommend the use of medical cannabis with a potency greater than three percent tetrahydrocannabinol to any minor for any qualifying medical condition. A minor may not legally use medical cannabis with a potency greater than three percent tetrahydrocannabinol, whether or not the minor has a valid medical cannabis card. A parent or legal guardian of a minor who holds a medical cannabis card may not legally possess medical cannabis with a potency greater than three percent tetrahydrocannabinol, unless the parent or guardian holds a valid medical cannabis card for his or her own qualifying medical condition.
Ala. Code § 20-2A-61 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-61
Section 20-2A-61 Advertisement and Display Restrictions
Status: in_force

(a)(1) With regard to any physical structure or vehicle owned, leased, or otherwise used by a licensee, the licensee may not do either of the following:

a. Advertise medical cannabis brand names or use graphics related to cannabis or paraphernalia on the exterior of the physical structure or vehicle.

b. Display medical cannabis products or paraphernalia so as to be clearly visible from the exterior of the physical structure or vehicle.

(2) Restrictions in this subsection shall apply to any item located on real property on which a licensee’s physical structures are located

(b) Advertising for medical cannabis may not contain any statements, illustrations, or other material that would be appealing to minors.

(c) The commission shall adopt rules that establish restrictions and requirements for advertising, including signage, that may include limiting the media or forums where advertising may occur.
Ala. Code § 20-2-23 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-23
Section 20-2-23 Schedule I - Listing of Controlled Substances
Status: in_force

(a) The Legislature finds the following:

(1) New synthetic substances are being created which are not controlled under the provisions of existing state law but which have a potential for abuse similar to or greater than that for substances controlled under existing state law. These new synthetic substances are called “synthetic controlled substances or synthetic controlled substance analogues” and can be designed to produce a desired pharmacological effect and to evade the controlling statutory provisions. Synthetic controlled substances or synthetic controlled substance analogues are being manufactured, distributed, possessed, and used as substitutes for controlled substances.

(2) The hazards attributable to the traffic in and use of a synthetic controlled substance or synthetic controlled substance analogues are increased because their unregulated manufacture produces variations in purity and concentration.

(3) Many new synthetic substances are untested, and it cannot be immediately determined whether they have useful medical or chemical purposes.

(4) The uncontrolled importation, manufacture, distribution, possession, or use of controlled substance analogues has a substantial and detrimental impact on the health and safety of the people of this state.

(5) Synthetic controlled substances or synthetic controlled substance analogues can be created more rapidly than they can be identified and controlled by action of the Legislature. There is a need for a speedy determination of their proper classification under existing law. It is therefore necessary to identify and classify new substances that have a potential for abuse, so that they can be controlled in the same manner as other substances controlled under existing state law.

(b) The controlled substances listed in this section are included in Schedule I:

(1) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

a. Acetylmethadol;

b. Allylprodine;

c. Alphacetylmethadol;

d. Alphameprodine;

e. Alphamethadol;

f. Benzethidine;

g. Betacetylmethadol;

h. Betameprodine;

i. Betamethadol;

j. Betaprodine;

k. Clonitazene;

l. Dextromoramide;

m. Dextrorphan;

n. Diampromide;

o. Diethylthiambutene;

p. Dimenoxadol;

q. Dimepheptanol;

r. Dimethylthiambutene;

s. Dioxaphetyl butyrate;

t. Dipipanone;

u. Ethylmethylthiambutene;

v. Etonitazene;

w. Etoxeridine;

x. Furethidine;

y. Hydroxypethidine;

z. Ketobemidone;

aa. Levomoramide;

bb. Levophenacylmorphan;

cc. Morpheridine;

dd. Noracymethadol;

ee. Norlevorphanol;

ff. Normethadone;

gg. Norpipanone;

hh. Phenadoxone;

ii. Phenampromide;

jj. Phenomorphan;

kk. Phenoperidine;

ll. Piritramide;

mm. Proheptazine;

nn. Properidine;

oo. Racemoramide;

pp. Trimeperidine.

(2) Any of the following opium derivatives, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

a. Acetorphine;

b. Acetyldihydrocodeine;

c. Benzylmorphine;

d. Codeine methylbromide;

e. Codeine-N-Oxide;

f. Cyprenorphine;

g. Desomorphine;

h. Dihydromorphine;

i. Etorphine;

j. Heroin;

k. Hydromorphinol;

l. Methyldesorphine;

m. Methyldihydromorphine;

n. Morphine methylbromide;

o. Morphine methylsulfonate;

p. Morphine-N-Oxide;

q. Myrophine;

r. Nicocodeine;

s. Nicomorphine;

t. Normorphine;

u. Pholcodine;

v. Thebacon.

(3) Any material, compound, mixture or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

a. 3,4-methylenedioxy amphetamine;

b. 5-methoxy-3,4-methylenedioxy amphetamine;

c. 3,4,5-trimethoxy amphetamine;

d. Bufotenine;

e. Diethyltryptamine;

f. Dimethyltryptamine;

g. 4-methyl-2,5-dimethoxy amphetamine;

h. Ibogaine;

i. Lysergic acid diethylamide;

j. Marihuana;

k. Mescaline;

l. Peyote;

m. N-ethyl-3-piperidyl benzilate;

n. N-methyl-3-piperidyl benzilate;

o. Psilocybin;

p. Psilocyn;

q. Tetrahydrocannabinols, except for tetrahydrocannabinols in hemp, as defined in Section 2-8-381.

(4)a. A synthetic controlled substance that is any material, mixture, or preparation that contains any quantity of the following chemical compounds, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation or compound:

1. 3,4-Methylenedioxymethcathinone (Methylone), some trade or other names: 3,4-methylenedioxy-N-methylcathinone.

2. 3,4-Methylenedioxypyrovalerone, some other trade names: (MDPV).

3. 4-Methylmethcathinone (Mephedrone), some trade or other names: 4-methylephedrone.

4. 4-Methoxymethcathinone (Methedrone), some trade or other names: bk-PMMA.

5. 3-Fluoromethcathinone, some trade or other names: 3-FMC.

6. 4-Fluoromethcathinone (Flephedrone), some trade or other names: 4-FMC.

7. 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone, some trade or other names: AM-694.

8. 1-[(5-fluoropentyl)-1H-indol-3-yl]-(naphthalen-1-yl)methanone, some trade or other names: AM-2201.

9. (6aR, 10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol, some trade or other names: HU-210.

10. (6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol, some trade or other names: HU-211, Dexanabinol.

11. 1-Pentyl-2-methyl-3-(1-naphthoyl)indole, some trade or other names: JWH-007.

12. (2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone, some trade or other names: JWH-015.

13. Naphthalen-1-yl-(1-pentylindol-3-yl)methanone, some trade or other names: JWH-018.

14. 1-Hexyl-3-(naphthalen-1-oyl)indole, some trade or other names: JWH-019.

15. Naphthalen-1-yl-(butylindol-3-yl)methanone, some trade or other names: JWH-073.

16. 4-Methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone, some trade or other names: JWH-081.

17. 4-Methoxynaphthalen-1-yl-(1-pentyl-2-methylindol-3-yl) methanone, some trade or other names: JWH-098.

18. 4-Methylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone, some trade or other names: JWH-122.

19. (1-(2-Morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone, some trade or other names: JWH-200.

20. 2-(2-Chlorophenyl)-1-(1-pentylindol-3-yl)ethanone, some trade or other names: JWH-203.

21. 4-Ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone, some trade or other names: JWH-210.

22. 2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone, some trade or other names: JWH-250.

23. 5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone, some trade or other names: JWH-307.

24. 1-Pentyl-3-(4-Chloro-1-naphthoyl)indole, some trade or other names: JWH-398.

25. 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol (Cannabicyclohexanol), some trade or other names: CP 47, 497, and homologues.

26. 2-(2-Methoxyphenyl)-1-[1-(2-cyclohexylethyl)indol-3-yl]ethanone, some trade or other names: RCS-8, SR-18.

27. 2-(4-Methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone, some trade or other names: RCS-4.

28. (R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone, some trade or other names: WIN 55,212-2.

29. (4-Methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]methanone, some trade or other names: WIN 48,098, Pravadoline.

b. In addition to any material, mixture, or preparation that contains any quantity of the chemical compounds listed in paragraph a., a synthetic controlled substance also includes the following chemical compounds, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation or compound:

1. 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole, some trade or other names: (AM-2233).

2. 1-Pentyl-3-(1-adamantoyl)indole, some trade or other names: (AB001).

3. [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-1-naphthalenyl-methanone, some trade or other names: (AM1220).

4. 1-(5-Fluoropentyl)-3-(2,2,3,3-tetramethylcyclopropyoyl)indole, some trade or other names: (XLR11).

5. 1-Pentyl-3-(2,2,3,3-tetramethycyclopropoyl)indole, some trade or other names: (UR-144).

6. 6-Methyl-2[(4-methylphenyl)amino]-4H-3,1-benzoxazin-4-one, some trade or other names: (URB 754).

7. [1,1′-biphenyl]-3-yl-carbamic acid, cyclohexyl ester, some trade or other names: (URB 602).

8. (3′-(Aminocarbonyl)[1,1′-biphenyl]-3-yl)-cyclohexylcarbamate, some trade or other names: (URB597).

9. 1-(5-Fluoropentyl)-3-(4-methyl-1-naphthoyl)indole, some trade or other names: (MAM2201).

10. 1-naphthalenyl[4-(pentyloxy)-naphthalenyl]methanone, some trade or other names: (CB-13).

11. 1-(5-Chloropentyl)-3-(2,2,3,3-tetramethylcyclopropoyl)indole, some trade or other names: (5-Chloro-UR-144).

12. 1-(5-Fluoropentyl)-N-tricyclo[3,3,1,13,7]dec-1-yl-1H-indole-3-carboxamide, some trade or other names: (STS-135).

13. 1[(N-Methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl)indole, some trade or other names: (AM1248).

14. N-Adamantyl-1-pentyl-1H-indole-3-carboxamide, some trade or other names: (SDB-001, 2NE1).

15. 1-Pentyl-N-tricyclo[3,3,1,13,7]dec-1-yl-1H-indazole-3-carboxamide, some trade or other names: (AKB48, APINACA).

16. 3-Naphthoylindole.

17. 1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3-tetramethylcyclopropyl)indole, some trade or other names: (A 796,260).

18. 1-[(tetrahydropyran-4-ylmethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone, some trade or other names: (A 834,735).

19. 1-(Pent-4-en-1-yl)-3-(4-methyl-1-naphthoyl)indole, some trade or other names: (JWH-122 4-pentenyl analog).

20. N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide some trade or other names: (AB-FUBINACA).

21. [1-(5-bromopentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone, some trade or other names: (5-Bromo-UR-144)

22. 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexylphenol, some trade or other names: (CP-47,497 C8 homolog).

23. 1-(5-Fluoropentyl)-N-tricyclo[3,3,1,13,7]dec-1-yl-1H-indazole-3-carboxamide, some trade or other names: (5F-AKB48, 5F-APINACA).

24. 1-(penta-4-ene)-3-(1-naphthoyl)indole, some trade or other names: (JWH-022).

25. 1-(5-Chloropentyl)-3-(1-naphthoyl)indole, some trade or other names: (Chloro-AM-2201, JWH-018 N-5-chloropentyl analog).

26. 1-(5-Hydroxypentyl)-3-(1-naphthoyl)indole, some trade or other names: (Hydroxy-AM-2201).

27. N-[(2E)-3-(2-Methoxyethyl)4,5-dimethyl-1,3-thiazole-2(3H)-ylidene]-2,2,3,3-tetramethylcyclopropane carboxamide, some trade or other names: (A 836,339).

28. 1-Pentyl-3-(2-iodobenzoyl)indole, some trade or other names: (AM 679).

29. 1-Pentyl-3-(2-methylphenacetyl)indole, some trade or other names: (JWH-251).

30. 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester, some trade or other names: (PB-22, QUPIC).

31. 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester, some trade or other names: (5F-PB-22).

32. 1-pentyl-N-(naphthalen-1-yl)-1H-indole-3-carboxamide, some trade or other names: (MN-24, NNE1).

33. 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester, some trade or other names: (BB-22, QUCHIC).

34. N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide, some trade or other names: (AB-PINACA).

35. 7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide, some trade or other names: (MN-25).

36. ADB-PINACA.

37. FUB-AKB-48.

38. FUB-PB-22.

39. Heptyl-UR144.

40. THJ-018.

41. THJ-2201.

42. 1-heptyl-3-(1-napthoyl)indole), some trade or other names: (JWH-20).

43. Napthalen-1-yl-(1-propyl-1H-indol-3-yl)methanone, some trade or other names: (JWH-072).

44. (6aR,10aR)-3-(1, 1-Dimethylbutyl)-6a, 7, 10, 10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran, some trade or other names: (JWH-133).

45. 3-(napthalen-1-ylmethyl)-1-pentyl-1H-indole, some trade or other names: (JWH-175).

46. 1-pentyl-3-(4-methoxyophenylacetyl)indole, some trade or other names: (JWH-201).

47. 1-pentyl-3-(3-methoxyphenylacetyl)indole, some trade or other names: (JWH 302).

48. [(1R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol, some trade or other names: (HU-308).

49. 3-hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione, some trade or other names: (HU-331).

50. N-cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-undecanamide, some trade or other names: (CB-25).

51. N-cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)-undecanamide, some trade or other names: (CB-52).

52. 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol, some trade or other names: (CB-55,940)(CB-55).

53. 4-Methylethylcathinone, some trade or other names: (4-MEC, 4-Methylethcathinone).

54. 4′-Methyl-alpha-pyrrolidinopropiophenone, some trade or other names: (MPPP, ZZ-1).

55. (RS)-1-naphthalen-2-yl-2-pyrrolidin-1-ylpentan-1-one, some trade or other names: (Naphyrone).

56. alpha,alpha-Diphenyl-2-piperidinemethanol, some trade or other names: (Pipradrol, Meratran).

57. (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)pentan-1-one, some trade or other names: (Pyrovalerone).

58. 3,4-Dimethylmethcathinone, some trade or other names: (3,4-DMMC).

59. 4-Fluoroamphetamine, some trade or other names: (4-FA).

60. 4-Fluoromethamphetamine, some trade or other names: (4-FMA).

61. Butylone, some trade or other names: (bk-MBDB).

62. alpha-Pyrrolidinopentiophenone, some trade or other names: (alpha-PVP).

63. beta-keto-Dimethylbenzodioxolylbutanamine, some trade or other names: (bk-DMBDB).

64. 2-(methylamino)-1-phenylbutan-1-one, some trade or other names: (Buphedrone).

65. (RS)-2-ethylamino-1-phenyl-propan-1-one, some trade or other names: (N-Ethylcathinone).

66. 2-Fluoroamphetamine, some trade or other names: (2-FA).

67. Methoxetamine, some trade or other names: (MXE).

68. 2-Methylamino-1-phenylpentan-1-one, some trade or other names: (Pentedrone).

69. 3,4-Methylenedioxycathinone, some trade or other names: (MDC).

70. 2-Fluoromethamphetamine, some trade or other names: (2-FMA).

71. 4-methylmethamphetamine, some trade or other names: (4-MMA).

72. 4-Fluoroisocathinone, some trade or other names: (4-FIC).

73. 3-Fluoromethamphetamine, some trade or other names: (3-FMA).

74. Methiopropamine, some trade or other names: (MPA).

75. alpha-Pyrrolidinobutiophenone, some trade or other names: (alpha-PBP).

76. 4-Methoxy-N-methylcathinone, some trade or other names: (Methedrone, bk-PMMA).

77. alpha-Pyrrolidinopropiophenone, some trade or other names: (alpha-PPP).

78. (RS)-2-benzhydrylpiperidine, some trade or other names: (Desoxypipradrol).

79. 3,4-Methylenedioxyethylcathinone, some trade or other names: (MDEC).

80. 3,4-Methylenedioxy-alpha-pyrrolidinobutiophenone, some trade or other names: (MDPBP).

81. 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (Pentylone, bk-MBDP).

82. 3-Fluoroamphetamine, some trade or other names: (3-FA).

83. 3-Fluoromethcathinone, some trade or other names: (3-FMC).

84. 2-Fluoromethcathinone, some trade or other names: (2-FMC).

85. 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)propan-1-one (bk-MDDMA).

86. N,N-Diethylcathinone, some trade or other names: (Amfepramone, DEC).

87. 1,3-Dimethylamylamine, some trade or other names: (DMAA).

88. N, N-Dimethylcathinone, some trade or other names: (DMC).

89. N-Ethyl-3,4-methylenedioxycathinone, some trade or other names: (bk-MDEA).

90. N-Ethylamphetamine, some trade or other names: (EMA).

91. N-Ethylcathinone, some trade or other names: (EC).

92. 2-Ethylethcathinone, some trade or other names: (2-EEC).

93. 4-Ethyl-N-ethylcathinone, some trade or other names: (4-EEC).

94. 2-(5-Methoxy-1-benzofuran-3-yl)-N,N-dimethylethanamine, some trade or other names: (Dimembfe).

95. 2-(5-Methoxy-1-benzofuran-3-yl)N-ethylethamine.

96. 4-Methoxymethamphetamine, some trade or other names: (PMMA).

97. 4-Methoxy-N-ethylamphetamine, some trade or other names: (PMEA).

98. 4-Methoxy-N-ethylcathinone, some trade or other names: (ETHEDRONE).

99. 3-Methylmethcathinone, some trade or other names: (3-MMC).

100. 4-Methyl-alpha-pyrrolidinobutiophenone, some trade or other names: (MPBP).

101. 2-Methylethcathinone, some trade or other names: (2-MEC).

102. 3-Methylethcathinone, some trade or other names: (3-MEC).

103. 2-Ethylethcathinone, some trade or other names: (2-EEC).

104. 3-Ethylethcathinone, some trade or other names: (3-EEC).

105. 3-Ethylmethcathinone, some trade or other names: (3-EMC).

106. 3′,4′-Methylenedioxy-alpha-pyrrolidinopropiophenone, some trade or other names: (MDPPP).

107. alpha-Pyrrolidinopentiothiophenone, some trade or other names: (alpha-PVT).

108. 3-Methoxymethcathinone, some trade or other names: (3-MeOMC).

109. N-Methyl-1,3-benzodioxolylbutanamine, some trade or other names: (MBDB).

110. Ethcathinone, some trade or other names: (ETHYLPROPION, ETH-CAT).

111. Ethylone (3,4-methylenedioxy-N-ethylcathinone).

112. N-N-Diethyl-3,4-methylenedioxycathinone.

113. 3,4-methylenedioxy-propiophenone.

114. 2-Bromo-3,4-methylenedioxypropiophenone.

115. 3,4-methylenedioxy-propiophenone-2-oxime.

116. N-Acetyl-3,4-methylenedioxycathinone.

117. N-Acetyl-N-Methyl-3,4-methylenedioxycathinone.

118. N-Acetyl-N-Ethyl-3,4-methylenedioxycathinone.

119. 4-Bromomethcathinone.

120. 3-Bromomethcathinone.

121. Eutylone (beta-Keto-Ethylbenzodioxolylbutanamine).

122. 4′-Methoxy-alpha-pyrrolidinopropiophenone, some trade or other names: (MOPPP).

123. 4′-Methyl-alpha-pyrrolidinohexiophenone, some trade or other names: (MPHP).

124. Benocyclidine (BCP) or Benzothiophenylcyclohexylpiperidine, some trade or other names: (BTCP).

125. 4-Fluoro-(methylamino)butyrophenone, some trade or other names: (F-MABP).

126. 3-Methyl-4-Methoxymethacathinone, some trade or other names: (3-Me-4-MeO-MCAT).

127. 4-Methyl-(ethylamino)-butryophenone, some trade or other names: (Me-EABP).

128. 4-Ethyl-methcathinone, some trade or other names: (4-EMC).

129. 4-methoxy-N-ethylcathinone (bk-PMC;p-methox-ethcathinone).

130. 4′-Methoxy-alpha-pyrroldino-propiophenone (MeOPPP; 4′-MeO-PPP).

131. 3-Fluorocathinone (3-FC).

132. 4-Fluorocathinone (4-FC).

133. 4-methyl-buphedrone (4-MeMABP; 4MeBP; BZ-6378).

134. 3,4-Methylenedioxy-N-benzylcathinone, some trade or other names: (BMDP).

135. N-Benzyl-butylone, some trade or other names: (BMDB).

136. N-Hydroxy-3,4-methlyenedioxymethcathinone.

137. N-ethylbuphedrone, some trade or other names: (NEB).

138. 4-Fluorobuphedrone, some trade or other names: (4-FBP).

139. 4-Methoxy-pyrrolidinbutrophenone (4-MeO-PBP).

140. 4-Ethyl-pyrrolidinobutrophenone, some trade or other names: (4-Et-PBP).

141. 5-(2-aminopropyl)indole, some trade or other names: (5-IT).

142. 1-phenyl-2-(piperidin-1-yl)butan-1-one.

143. 2,4,5-Trimethyl-methacathinone, some trade or other names: (2,4,5-TMMC).

144. alpha-pyrrolidino-heptiophenone, some trade or other names: (alpha-PHpP).

145. 4-Methylamphetamine (4-MA: pTAP; PAL-313; 4-MeA; PmeA).

146. N-Ethyl-methamphetamine.

147. 4-(2-Aminopropyl)benzofuran, some trade or other names: (4-APB).

148. 5-(2-Aminopropyl)-2,3-dihydro-1H-indene (5-APDI; IAP; AIP; indanylaminoporpane).

149. 6,7-Methylenedioxy-2-aminotetralin, some trade or other names: (MDAT).

150. 4-Methylthioamphetamine (4-MTA; P1882).

151. 4-Chloroamphetamine (p-chloro-amphetamine).

152. 2,4,6-Trimethoxyamphetamine, some trade or other names: (TMA-6).

153. 2,4,5-Trimethoxyamphetamine, some trade or other names: (TMA-2).

154. 2,5-Dimethylamphetamine, some trade or other names: (2,5-DMA).

155. 3,4-Dimethylamphetamine, some trade or other names: (3,4-DMA).

156. N-propylamphetamine.

157. 4-Hydroxyamphetamine.

158. 3-Hydroxyamphetamine.

159. Methylenedioxydimethylamphetamine, some trade or other names: (MDDM).

160. 2-Aminoindane, some trade or other names: (2-AI).

161. 5,6-Methylenedioxy-N-methyl-aminoindane, some trade or other names: (MDMAI).

162. 2C-T-21.

163. 2C-B-Fly.

164. 3,4-dimethyl-2,5-dimethoxyphenethylamine (2C-G).

165. 25D-NBOMe.

166. 25G-NBOMe.

167. 25N-NBOMe.

168. Bromo-benzyldifuranyl-isopropylamine, some trade or other names: (Bromo Dragon Fly).

169. 3C-B fly.

170. 2,5-Dimethoxy-4-ethylthioamphetamine, some trade or other names: (Aleph-2).

171. 1-[(4-ethoxy-2,5-dimethoxy)phenyl]propan-2-amine, some trade or other names: (MEM).

172. 1-[2,5-dimethoxy-4-(propylthio)phenyl]propan-2-amine, some trade or other names: (Aleph-7).

173. N-benzyl-2-phenylethylanamine.

174. N,N-dimethyl-2-phenylethanamine.

175. 6-chloro-2-aminotetralin, some trade or other names: (6-CAT).

176. 2-phenylpropan-1-amine, some trade or other names: (B-Me-PEA).

177. 2-Phenethylamine, some trade or other names: (2-PEA).

178. 1-methylamino-1-(3,4-methylenedioxyphenyl)propane, some trade or other names: (M-ALPHA).

179. Camfetamine.

180. Methoxyphenamine.

181. 4-methylaminorex, some trade or other names: (4-MAR; 4-MAX; U4Euh; Euphoria; Ice).

182. (1-thiophen-2-yl)propan-2-amine (Thienoamphetamine).

183. Dimethocaine.

184. 4-Fluoroephedrine.

185. 4-methyaminorex (p-methyl derivative).

186. 1-[(N-methylpiperidin-2-yl)methyl]-2-methyl-3-(naphthalen-1-oyl)-6-nitroindole (AM1221).

187. (1-butyl-1H-indol-3-yl)(4-methoxyphenyl)-methanone (RCS-4 (C4) homolog).

188. 5-[3-(1-naphthoyl)-1H-indole-1-yl]pentanenitrile, some trade or other names: (AM2232).

189. 1-(Pentyl)-3-(4-bromo-1-naphthoyl)-indole, some trade or other names: (JWH-387).

190. 1-(Pentyl)-3-(4-fluoro-1-naphthoyl)-indole, some trade or other names: (JWH-412).

191. 1-(5-chlorpentyl)-3-(2-iodobenzoyl)indole, some trade or other names: (AM694 Derivative).

192. (2-iodo-5-nitrophenyl)-[1-[(1-methylpiperidin-2-yl]methyl]1H-indol-3-yl]-methanone, some trade or other names: (AM1241).

193. 1-Pentyl-3-[1-(4-propyl)naphthoyl]indole, some trade or other names: (JWH-182).

194. JWH-081 2-methoxynaphthyl isomer, some trade or other names: (JWH-267).

195. (3-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone, some trade or other names: (RCS-4 3-methoxy isomer).

196. [1-(5-fluoropentyl)-1H-indol-3-yl](4-ethyl-1-naphthalenyl)-methanone (EAM-2201).

197. ADB-FUBINACA.

198. ADBICA.

199. AM-279.

200. JWH-370.

201. NNE-1.

202. MAM-2201 chloropentyl derivative.

203. 1-(5-fluoropentyl)-3-(2-methyl-benzoyl)indole.

204. 1-(5-fluoropentyl)-3-(2-ethylbenzoyl)indole.

205. AB-005.

206. AB-005 Azepane isomer.

207. 4-hydroxy-3,3,4-trimethyl-1-(1-pentyl-1H-indol-3-yl)pentan-1-one (4-HTMPIPO).

208. UR-12.

209. 5-Fluoro-ADBICA.

210. BAY-38-7271; KN 38-7271.

211. JTE-907.

212. Org 27569.

213. Org 27759.

214. Org 29647.

215. LY 2183240.

216. JTE 7-31.

217. URB 937.

218. 3-methoxy-eticyclidine, some trade or other names: (3-MeO-PCE).

219. 1-Phenylcyclohexanamine, some trade or other names: (PCA).

220. 4-Methyl-phencyclidine, some trade or other names: (4-Me-PCP).

221. 4-Methoxy-eticyclidine, some trade or other names: (4-MeO-PCE).

222. 4-Methoxyphencyclidine, some trade or other names: (Methoxydine; 4MeO-PCP).

223. 3-Methoxyphencyclidine, some trade or other names: (3-MeO-PCP).

224. 1-phenyl-N-propylcyclohexanamine, some trade or other names: (PCPr).

225. N-(2-methoxyethyl)-1-phenylcyclohexanamine, some trade or other names: (PCMEA).

226. N-(2-ethoxyethyl)-1-phenylcyclohexanamine, some trade or other names: (PCEEA).

227. N-(3-methoxypropyl)-1-phenylcyclohexanamine, some trade or other names: (PCMPA).

228. 3-Hydroxy-phencyclidine, some trade or other names: (3-OH-PCP).

229. Methoxyketamine, some trade or other names: (2-MeO-2-deschloro-ketamine).

230. Tiletamine, some trade or other names: (TCE).

231. N-ethylnorketamine.

232. N-Methyltryptamine, some trade or other names: (NMT).

233. N-Methyl-N-isopropyltryptamine, some trade or other names: (MiPT; MIPT).

234. 4-hydroxy-N,N-methylisopropyltryptamine, some trade or other names: (4-OH-MiPT).

235. 4-Acetoxy-N,N-diisopropyl-tryptamine (4-AcO-DiPT: 4-AcO-DIPT; 4-Acetoxy-MiPT).

236. 4-Methoxy-N,N-dimethyltryptamine, some trade or other names: (4-MeO-DMT).

237. 5-Hydroxytryptamine, some trade or other names: (5-HT).

238. 5-acetoxy-N,N-dimethyltryptamine, some trade or other names: (5-AcO-DMT).

239. 5-Methoxy-N,N-dipropyltryptamine, some trade or other names: (5-MeO-DPT).

240. d-Lysergic acid amide, some trade or other names: (LSA; ergine).

241. 2,5-dimethoxy-4-chloroamphetamine, some trade or other names: (DOC).

242. N-(2-Methoxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, some trade or other names: (25I-NBOMe).

243. 4-Ethyl-2,5-dimethoxyphenethylamine, some trade or other names: (2C-E).

244. 2,5-Dimethoxy-4-iodophenethylamine, some trade or other names: (2C-I).

245. 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, some trade or other names: (6-APDB).

246. 6-(2-Aminopropyl)benzofuran, some trade or other names: (6-APB).

247. 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, some trade or other names: (5-APDB).

248. 5-(2-Aminopropyl)benzofuran, some trade or other names: (5-APB).

249. 2,5-Dimethoxy-4-(n)-propylthiophenethylamine, some trade or other names: (2C-T-7).

250. 2,5-Dimethoxy-4-(n)-propylphenethylamine, some trade or other names: (2C-P).

251. 2,5-Dimethoxy-4-bromoamphetamine, some trade or other names: (DOB).

252. 2,5-Dimethoxy-4-bromobenzylpiperazine, some trade or other names: (2C-B-BZP).

253. 2,5-Dimethoxy-4-bromophenethylamine, some trade or other names: (2C-B).

254. 2,5-Dimethoxy-4-chlorophenethylamine, some trade or other names: (2C-C).

255. 2,5-Dimethoxy-(4-ethylthio)phenethylamine, some trade or other names: (2C-T-2).

256. 2,5-Dimethoxy-4-iodoamphetamine, some trade or other names: (DOI).

257. 2,5-Dimethoxy-4-methylamphetamine, some trade or other names: (DOM).

258. 2,5-Dimethoxyphenethylamine, some trade or other names: (2C-H).

259. 2-(2,5-Dimethoxyphenyl-4-bromo)-N-(2-methoxybenzyl)ethanamine, some trade or other names: (25B-NBOMe).

260. 2-(2,5-Dimethoxyphenyl-4-chloro)-N-(2-methoxybenzyl)ethanamine, some trade or other names: (25C-NBOMe).

261. 2-(2,5-Dimethoxyphenyl-4-ethyl)-N-(2-methoxybenzyl)ethanamine, some trade or other names: (25E-NBOMe).

262. 2-Ethylmethcathinone, some trade or other names: (2-EMC).

263. 2-(2,5-Dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, some trade or other names: (25H-NBOMe).

264. BZP (Benzylpiperazine).

265. para-Fluorophenylpiperazine.

266. 1-(4-Methylphenyl)piperazine.

267. meta-Cholorophenylpiperazine.

268. para-Methoxyphenylpiperazine.

269. DBZP (1,4-dibenzylpiperazine).

270. TFMPP (3-Trifluoromethylphenylpiperazine).

271. 2C-T-4 (2,5-Dimethoxy-4-isopropylthiophenethylamine.

272. 2C-T (2,5-Dimethoxy-4-methylthiophenethylamine).

273. 2C-D (2-(2,5-Dimethoxy-4-methylphenyl)ethanamine).

274. 2C-N 2,5-Dimethoxy-4-nitrophenethylamine.

275. 5-methoxy-N,N-diallyltryptamine, some trade or other names: (5-MeO-DALT).

276. 5-Methoxy-N,N-Diisopropyltryptamine, some trade or other names: (5-MeO-DIPT).

277. 5-Methoxy-alpha-methyltryptamine, some trade or other names: (5-MeO-AMT).

278. 4-Acetoxy-N,N-dimethyltryptamine, some trade or other names: (4-AcO-DMT).

279. 4-Hydroxy-N,N-diethyltryptamine, some trade or other names: (4-HO-DET).

280. 4-Hydroxy-N,N-diisopropyltryptamine, some trade or other names: (4-HO-DIPT).

281. 4-Hydroxy-N-methyl-N-ethyltryptamine, some trade or other names: (4-OH-MET).

282. 5-Methoxy-N,N-diethyltryptamine, some trade or other names: (5-MeO-DET).

283. 5-Methoxy-N-methyl-N-isopropyltryptamine, some trade or other names: (5-MeO-MIPT).

284. 4-Acetoxy-N,N-diethyltryptamine, some trade or other names: (4-AcO-DET).

285. 4-Acetoxy-N-methyl-N-isopropyltryptamine, some trade or other names: (4-AcO-MIPT).

286. N,N-Dipropyltryptamine, some trade or other names: (DPT).

287. N,N-Diisopropyltryptamine, some trade or other names: (DIPT).

288. 4-Methoxy-N-methyl-N-isopropyltryptamine, some trade or other names: (4-MeO-MIPT).

289. Tyramine (4-Hydroxyphenethylamine).

290. 5-Hydroxy-alpha-methyltryptamine.

291. 5-Hydroxy-N-methyltryptamine.

292. 5-Methoxy-N,N-dimethyltryptamine.

293. 5-Methyl-N,N-dimethyltryptamine.

294. Diphenylprolinol, some trade or other names: (D2PM; diphenyl-2-pyrrolidinemethanol).

295. 3,4 Dichloromethylphenidate, some trade or other names: (3,4-CTMP).

296. 3-chloromethyl-phenidate, some trade or other names: (3-CTMP).

297. 4-Methylmethylphenidate.

298. 4-Fluoromethyl-phenidate, some trade or other names: (4-FTMP).

299. Ethylphenidate.

300. Etizolam (Etilaam, Etizola, Sedekopan, Pasaden, Depas).

301. Phenazepam.

302. Pyrazolam.

303. CL-218,872.

304. Zopiclone.

305. Salvinorin A.

306. AH-7921.

307. O-Desmethyltramadol, some trade or other names: (O-DT; ODT).

308. Desmorphine (Dihydrodesoxymorphine; permonid; krokodil; crocodile).

309. Acetyl Fentanyl (desmethylfentanyl).

310. 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45).

311. 1-(2-methoxyphenyl)piperazine, some trade or other names: (MOPIP).

312. 1-(4-Chlorophenyl)piperazine, some trade or other names: (pCPP).

313. para-Methoxyphenyl-piperazine, some trade or other names: (MBZP).

314. Methylmethaqualone.

315. Etaqualone.

316. 5-Iodo-2-aminoindane, some trade or other names: (5-IAI).

317. 5,6-(Methylenedioxy)-2-aminoindane, some trade or other names: (5,6-MDAI).

318. 4,5-(Methylenedioxy)-2-aminoindane, some trade or other names: (4,5-MDAI).

319. MMAI.

320. W-15.

321. W-18.

322. Mitragynine.

323. Hydroxymitragynine.

324. Butyrfentanyl (N-phenyl-N-[1-(2-phenylethyl)-4-pyridinyl]butyramide).

325. Beta-Hydroxythiofentanyl (N-phenyl-N-{1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperdinyl}-propanamide).

326. 4-methylphenethyl acetyl fentanyl (N-phenyl-N-{1-[2-(4-methylphenyl)ethyl]-4-piperdinyl}-acetamide).

327. Acrylfentanyl (N-phenyl-N-[1-(2-phenylethyl)-4-piperdinyl]-prop-2-enamide).

328. 3-Allylfentanyl (N-phenyl-N-[1-(2-phenylethyl)-(3s,4R)-3-prop-2-enyl-4-piperidinyl]-propanamide).

329. Benzodioxole fentanyl (N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-benzo[d][1,3]dioxole-5-carboxamide).

330. Benzyl carfentanil (N-phenyl-N-(1-benzyl-4-methylcarboxylate-4-piperidinyl)-propanamide).

331. Brifentanil (N-(2-fluorophenyl)-N-{(3R,4S)-1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-3-methyl-4-piperdinyl}-2-methoxyacetamide).

332. Cyclopentylfentanyl (N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl)-cyclopentanecarboxamide).

333. 2,5-Dimethylfentanyl (N-phenyl-N-[1-(2-phenylethyl)-2,5-dimethyl-4-piperidinyl]-propranamide).

334. 4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl)-isobutyramide).

335. Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide).

336. Furanylethyl fentanyl (N-phenyl-N-[1-(2-furanylethyl)-4-piperidinyl]-propanamide).

337. Isobutyryl fentanyl (N-phenyl-N-[1-(2-phenylethyl)-4-piperdinyl]-2-methylpropanamide).

338. Lofentanil (N-phenyl-N-[1-(2-phenylethyl)-(3R,4S)-3-methyl-4-methylcarboxylate-4-piperidinyl]-propanamide).

339. 4-Methoxybutyrfentanyl (N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butyramide).

340. 4-Methoxymethylfentanyl (N-phenyl-N-[1-(2-phenylethyl)-4-methoxymethyl-4-piperidinyl]-propanamide).

341. Meta-fluorobutyryl fentanyl (N-(3-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidnyl)-butyramide).

342. Meta-fluorofentanyl (N-(3-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidnyl)-propanamide).

343. 3-Methylbutyrfentanyl (N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butyramide).

344. N-Methylcarfentanyl (N-phenyl-N-(1-methyl-4-methylcarboxylate-4-piperidinyl)-propanamide).

345. Methoxyacetylfentanyl (N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-methoxyacetamide).

346. Mirfentanyl (N-(2-pyrazinyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-2-furamide).

347. Ocfentanil (N-(2-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperdinyl]-2-methoxyacetamide).

348. Ohmefentanyl (N-phenyl-N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-propanamide).

349. Ortho-fluorobutyryl fentanyl (N-(2-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidnyl)-butyramide).

350. Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidnyl)-propanamide).

351. Para-chlorofentanyl (N-(4-chlorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide).

352. Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-isobutyramide).

353. 4-Fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butyramide).

354. Para-methoxyfentanyl (N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide).

355. Para-methylfentanyl (N-(4-methylphenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide).

356. 4-Phenyl fentanyl (N-phenyl-N-[4-phenyl-1-(2-phenylethyl)-4-piperidinyl]-propanamide).

357. Trefentanyl (N-(2-fluorophenyl)-N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-phenyl-4-piperdinyl}-propanamide).

358. Valeryl fentanyl (N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-pentanamide).

359. Alpha-Methylacetylfentanyl (N-phenyl-N-[1-phenylpropan-2-yl)-4-piperidinyl]-acetamide).

360. Alpha-Methylbutyrfentanyl (N-phenyl-N-[1-phenylpropan-2-yl)-4-piperidinyl]-butyramide).

361. Alpha-Methylthiofentanyl (N-phenyl-N-[1-(1-thienyl-2-ylpropan-2-yl)-4-piperidinyl]-propanamide).

362. Beta-Hydroxy fentanyl (N-phenyl-N-[1-(2-hydroxy-2-phenylethyl)-4-piperidinyl]-propanamide).

363. Beta-Methyl fentanyl (N-phenyl-N-[1-(2-phenylpropyl)-4-piperdinyl]-propanamide).

364. U-47700 (3,4-Dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide).

365. W-19 ((Z)-N-{1-[2-(4-aminophenyl)ethyl]piperidin-2-ylidene}-4-chlorobenzenesulfonamide).

366. Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine).

367. Tianeptine.

(5)a. A synthetic controlled substance analogue, being a material, mixture, or preparation that contains any chemical structure of which is chemically similar to the chemical structure of any other controlled substance in Schedule I or Schedule II or that satisfies any one of the following:

1. Has a stimulant, depressant, or hallucinogenic effect on the central nervous system that mimics or is similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in Schedule I or Schedule II.

2. With respect to a particular person, if the person represents or intends that the substance have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in Schedule I or Schedule II and the substance is actually capable of producing a stimulant, depressant, or hallucinogenic effect on the central nervous system that mimics, is similar to, or is greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in Schedule I or Schedule II.

3. Has been demonstrated to have binding activity at one or more cannabinoid receptors.

4. Is capable of exhibiting cannabinoid-like activity.

5. Any compound structurally analogous to, mimicking, or derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkyl halide, aryl halide, alkyl aryl halide, alkenyl, aliphatic alcohol, cycloalkylmethyl, cycloalkylethyl, (N-alkylpiperidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, or 2-(4-morpholinyl)ethyl whether or not further substituted in the indole ring to any extent, whether or not substituted in the naphthyl ring to any extent.

6. Any compound structurally analogous to, mimicking, or derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkyl halide, aryl halide, alkyl aryl halide, alkenyl, aliphatic alcohol, cycloalkylmethyl, cycloalkylethyl, (N-alkylpiperidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent.

7. Any compound structurally analogous to, mimicking, or derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, alkyl halide, aryl halide, alkyl aryl halide, alkenyl, aliphatic alcohol, cycloalkylmethyl, cycloalkylethyl, (N-alkylpiperidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, or 2-(4-morpholinyl)ethyl whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent.

8. Any compound structurally analogous to, mimicking, or derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkyl halide, aryl halide, alkyl aryl halide, alkenyl, aliphatic alcohol, cycloalkylmethyl, cycloalkylethyl, (N-alkylpiperidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent.

9. Any compound structurally analogous to, mimicking, or derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, alkyl halide, aryl halide, alkyl aryl halide, alkenyl, aliphatic alcohol, cycloalkylmethyl, cycloalkylethyl, (N-alkylpiperidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, or 2-(4-morpholinyl)ethyl, whether or not substituted in the cyclohexyl ring to any extent.

10. Any compound structurally analogous to, mimicking, or derived from 3-(2,2,3,3-tetramethylcyclopropoyl)indole or 1H-indol-3-yl-(2,2,3,3-tetramethylcyclopropoyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkyl halide, aryl halide, alkyl aryl halide, alkenyl, aliphatic alcohol, cycloalkylmethyl, cycloalkylethyl, (N-alkylpiperidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, or 2-(4-morpholinyl)ethyl whether or not further substituted in the indole ring to any extent.

11. Any compound structurally analogous to, mimicking, or derived from 3-(adamant-1-oyl)indole or 1H-indol-3-yl-(1-adamantyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkyl halide, aryl halide, alkyl aryl halide, alkenyl, aliphatic alcohol, cycloalkylmethyl, cycloalkylethyl, (N-alkylpiperidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, or 2-(4-morpholinyl)ethyl whether or not further substituted in the indole ring to any extent.

12. Any compound structurally analogous to, mimicking, or derived from N-(1-naphthalenyl)indole-3-carboxyamide or 1H-indol-(N-naphthyl)-3-carboxamide by substitution at the nitrogen atom of the indole ring by alkyl, alkyl halide, aryl halide, alkyl aryl halide, alkenyl, aliphatic alcohol, cycloalkylmethyl, cycloalkylethyl, (N-alkylpiperidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, or 2-(4-morpholinyl)ethyl whether or not further substituted in the indole ring to any extent, whether or not substituted in the naphthyl ring to any extent.

13. Any compound structurally analogous to, mimicking, or derived from N-(adamantan-1yl)indole-3-carboxyamide or 1H-indol-3-carboxamide-(1-adamantyl) by substitution at the nitrogen atom of the indole ring by alkyl, alkyl halide, aryl halide, alkyl aryl halide, alkenyl, aliphatic alcohol, cycloalkylmethyl, cycloalkylethyl, (N-alkylpiperidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, or 2-(4-morpholinyl)ethyl whether or not further substituted in the indole ring to any extent.

14. Any compound structurally analogous to, mimicking, or derived from N-(adamantan-1yl)indazole-3-carboxyamide or 1H-indazole-3-carboxamide-(1-adamantyl) by substitution at the nitrogen atom of the indazole ring by alkyl, alkyl halide, aryl halide, alkyl aryl halide, alkenyl, aliphatic alcohol, cycloalkylmethyl, cycloalkylethyl, (N-alkylpiperidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, or 2-(4-morpholinyl)ethyl whether or not further substituted in the indazole ring to any extent.

15. Any compound structurally analogous to, mimicking, or derived from N-[(1S)-1-(aminocarbonyl)-2-methylpropoyl]indazole-3-carboxyamide or 1H-indazole-3-carboxamide-N-[(1S)-1-(aminocarbonyl)-2-methylpropoyl] by substitution at the nitrogen atom of the indazole ring by alkyl, alkyl halide, aryl halide, alkyl aryl halide, alkenyl, aliphatic alcohol, cycloalkylmethyl, cycloalkylethyl, (N-alkylpiperidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, or 2-(4-morpholinyl)ethyl whether or not further substituted in the indazole ring to any extent.

16. Any compound structurally analogous to, mimicking, or derived from 3-(1-naphthoyl)indazole or 1H-indazole-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indazole ring by alkyl, alkyl halide, aryl halide, alkyl aryl halide, alkenyl, aliphatic alcohol, cycloalkylmethyl, cycloalkylethyl, (N-alkylpiperidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, or 2-(4-morpholinyl)ethyl whether or not further substituted in the indazole ring to any extent, whether or not substituted in the naphthyl ring to any extent.

17. Any compound structurally analogous to, mimicking, or derived from 3-(carboxylic acid 8-quinolinyl ester)indole or 1H-indol-3-carboxylic acid-(8-quinolinyl)ester by substitution at the nitrogen atom of the indole ring by alkyl, alkyl halide, aryl halide, alkyl aryl halide, alkenyl, aliphatic alcohol, cycloalkylmethyl, cycloalkylethyl, (N-alkylpiperidin-2-yl)methyl, (tetrahydropyran-4-yl)methyl, or 2-(4-morpholinyl)ethyl whether or not further substituted in the indole ring to any extent, whether or not substituted in the quinoline ring to any extent.

18. Any compound structurally related to 2-(4-iodo-2,5-dimethoxyphenyl) ethanamine by substitution of the iodo moiety (4 position) with other halides, alkyl, alkyl halides, thioalkyl, cycloalkyl, cycloalkylhalides and/or substitution at the nitrogen atom of the ethanamine with alkyl, alkyl halide, alkenyl, cycloalkylmethyl, cycloalkylethyl, phenyl, benzyl whether or not further substituted in the (either) phenyl ring to any extent.

19. Any compound structurally related to 2,5-dimethoxy-4-chloroamphetamine by substitution of the chloro moiety (4 position) with other halides, alkyl, alkyl halides, thioalkyl, cycloalkyl, cycloalkylhalides and/or substitution at the nitrogen atom with alkyl, alkyl halide, alkenyl, cycloalkylmethyl, cycloalkylethyl, phenyl, benzyl whether or not further substituted in the (either) phenyl ring to any extent.

20. Any compound structurally related to 2-amino-1-phenyl-1-propanone (cathinone) by substitution of the amine with alkyl, alkyl halide, alkenyl, cycloalkylmethyl, cycloalkylethyl, phenyl, benzyl whether or not further substituted in the (either) phenyl ring to any extent.

21. Any compound structurally related to a-pyrrolidinopentiophenone (a-pvp) whether or not further substituted in the phenyl ring to any extent, whether or not further substituted in the pyrrolidine ring to any extent.

b. A synthetic controlled substance or analogue in subdivision (4) or this subdivision does not include any of the following:

1. Any substance for which there is an approved new drug application under the Federal Food, Drug, and Cosmetic Act.

2. With respect to a particular person, any substance, if an exemption is in effect for investigational use, for that person, as provided by 21 U.S.C. § 355, and the person is registered as a controlled substance researcher as required under section 152.12, subdivision 3, to the extent conduct with respect to the substance is pursuant to the exemption and registration.

c. A controlled substance analogue is treated as a controlled substance in Schedule I.

d. After the Alabama Department of Forensic Sciences has determined a substance to be a synthetic controlled substance analogue under this section, the department shall notify the Alabama Department of Public Health with information relevant to scheduling as provided by Section 20-2-20.
Ala. Code § 20-1-54 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-54
Section 20-1-54 Effect of Possession by Manufacturer, Etc., of Adulterated or Misbranded Cosmetics
Status: in_force

The having in possession of an adulterated or misbranded cosmetic shall be prima facie evidence of having it in possession with the intent to sell it in violation of this division; provided, that a manufacturer, wholesaler, or jobber may keep such products set apart in his stock for sale in other states if he properly identifies them, although the possession of such products might otherwise be in violation of this division.
Ala. Code § 20-1-56 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-56
Section 20-1-56 Construction of Division
Status: in_force

This division shall be construed to be supplemental to Division 1 of this article, which relates to the regulation of the manufacture, possession, and sale of food and drugs.
Ala. Code § 20-2-302 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-302
Section 20-2-302 Construction of Article
Status: reserved

THIS SECTION REPEALED BY ACT 2023-339, EFFECTIVE SEPTEMBER 1, 2023.

Because the intent of the Legislature in this article is to educate physicians and to mitigate patient abuse and diversion of buprenorphine, nothing in this article shall modify, amend, repeal, or supersede any provision of Section 6-5-333, the Alabama Medical Liability Act of 1987, commencing with Section 6-5-540, the Alabama Medical Liability Act of 1996, commencing with Section 6-5-548, any amendment to any of the foregoing, or any judicial interpretation of any of the foregoing, nor shall anything in this article modify, amend, repeal, or supersede the law of or pertaining to the standard of care and admissibility of evidence regarding the standard of care.
Ala. Code § 20-2-120 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-120
Section 20-2-120 Penalties
Status: in_force

Any person or any practitioner who prescribes or dispenses cannabis or any of its derivatives for reasons other than outlined in this article upon conviction thereof shall be guilty of a felony and shall be punished as provided in Section 13A-12-211.
Ala. Code § 20-1-135 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-135
Section 20-1-135 Requirements as to Labeling Generally; When Package or Container Deemed Misbranded
Status: in_force

(a) The container shall be labeled “Mellorine - A Vegetable Oil Product.” When mellorine is made with animal fat it shall be labeled “Mellorine - Containing Animal Fat.” When mellorine is made with vegetable oil and animal fat it shall be labeled “Mellorine - Containing Vegetable Oil and Animal Fat.” The lettering of the word “Mellorine” shall in every case appear in as large type size and as prominent as any other wording on the container except the brand name but in no event shall it be smaller than 30 point Gothic type. The number of U.S.P. units due to the addition of vitamin A must appear on the label. The use of the word “cream” or its phonetic equivalent, however spelled in connection with the labeling, advertising, branding, or sale of mellorine, is hereby prohibited. The container or package in which mellorine is sold or offered for sale shall be deemed to be misbranded if mellorine is sold or offered for sale in violation of Sections 20-1-20 and 20-1-25. Mellorine sold or offered for sale in violation of this section is hereby prohibited.
Ala. Code § 20-2A-22 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-22
Section 20-2A-22 Implementation of Chapter; Administration and Enforcement
Status: in_force

(a) The Alabama Medical Cannabis Commission shall implement this chapter by making medical cannabis derived from cannabis grown in Alabama available to registered qualified patients and by licensing facilities that process, transport, test, or dispense medical cannabis.

(b) The commission shall administer and enforce this chapter and all rules adopted pursuant to this chapter.
Ala. Code § 20-2-30 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-30
Section 20-2-30 Schedule V - Standards for Compilation
Status: in_force

The State Board of Health shall place a substance in Schedule V if it finds that:

(1) The substance has low potential for abuse relative to the controlled substances listed in Schedule IV;

(2) The substance has currently accepted medical use in treatment in the United States; and

(3) The substance has limited physical dependence or psychological dependence liability relative to the controlled substances listed in Schedule IV.
Ala. Code § 20-2A-54 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-54
Section 20-2A-54 Statewide Seed-to-Sale Tracking System
Status: in_force

(a) In order to ensure that all medical cannabis sold in the state maintains product quality to protect the health and welfare of state residents, the commission shall establish a statewide seed-to-sale tracking system for use as an integrated cannabis and medical cannabis tracking, inventory, and verification system. The system must allow for interface with third-party inventory and tracking systems as described in Section 20-2A-60 to provide for access by this state, licensees, and law enforcement personnel, to the extent that they need and are authorized to receive or submit the information, to comply with, enforce, or administer this chapter.

(b) At a minimum, the system must be capable of storing and providing access to information that, in conjunction with the patient registry and with one or more third-party inventory control and tracking systems under Section 20-2A-60, allows all of the following:

(1) Retention of a record of the date, time, amount, and price of each sale or transfer of medical cannabis to a registered qualified patient or registered caregiver.

(2) Effective seed-to-sale tracking of cannabis and medical cannabis sales and transfers among licensees and with regard to integrated facility licensees, among facilities of the licensee.

(3) Receipt and integration of information from third-party inventory control and tracking systems under Section 20-2A-60.

(c) The commission shall seek bids to establish, operate, and maintain the statewide seed-to-sale tracking system under this section. The commission shall do all of the following:

(1) Evaluate bidders based on the cost of the service and the ability to meet all of the requirements of this chapter.

(2) Give strong consideration to the bidder’s ability to prevent fraud, abuse, and other unlawful or prohibited activities associated with the commercial trade in cannabis and medical cannabis in this state, and the ability to provide additional tools for the administration and enforcement of this chapter.

(3) Institute procedures to ensure that the person awarded the contract does not disclose or use the information in the system for any use or purpose except for the enforcement, oversight, and implementation of this chapter.

(4) Require the person awarded the contract to deliver the functioning system by 180 days after award of the contract.

(d) The commission may terminate a contract with the person awarded the contract for a violation of this chapter.

(e) The information in the statewide seed-to-sale tracking system is confidential and is exempt from disclosure under the Open Records Act, Article 3 of Chapter 12 of Title 36; provided, however, information in the system may be disclosed for purposes of enforcing this chapter.
Ala. Code § 20-2B-16 — Alabama Code / Title 20 / Chapter 2B / Section 20-2B-16
Section 20-2B-16 Repeal and Applicability of Article
Status: reserved

THIS SECTION WAS REPEALED BY ACT 2025-447, EFFECTIVE JUNE 1, 2025.
Ala. Code § 20-2-55 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-55
Section 20-2-55 Registration of Persons Manufacturing, Distributing or Dispensing Controlled Substances - Revocation or Suspension of Registration - Suspension Without Prior Order to Show Cause
Status: in_force

The certifying boards may suspend, without an order to show cause, any registration simultaneously with the institution of proceedings under Section 20-2-54 or where renewal of registration is refused, if it finds that there is an imminent danger to the public health or safety which warrants this action. The suspension shall continue in effect until the conclusion of the proceedings, including judicial review thereof, unless sooner withdrawn by the certifying boards or dissolved by a court of competent jurisdiction.
Ala. Code § 20-1-161 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-161
Section 20-1-161 Manufacture, Sale, or Distribution of Cultivated Food Products Prohibited
Status: in_force

(a) It shall be unlawful for any person to manufacture, sell, hold or offer for sale, or distribute any cultivated food product in this state.

(b) A violation of this section is a Class C misdemeanor.
Ala. Code § 20-2-213 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-213
Section 20-2-213 Reporting Requirements
Status: in_force

(a) Each of the entities designated in subsection (b) shall report to the department, or to an entity designated by the department, controlled substances prescription information as designated by regulation pertaining to all Class II, Class III, Class IV, and Class V controlled substances in such manner as may be prescribed by the department by regulation.

(b) The following entities or practitioners are subject to the reporting requirements of subsection (a):

(1) Licensed pharmacies, not including pharmacies of general and specialized hospitals, nursing homes, and any other health care facilities which provide inpatient care, so long as the controlled substance is administered and used by a patient on the premises of the facility.

(2) Mail order pharmacies or pharmacy benefit programs filling prescriptions for or dispensing controlled substances to residents of this state.

(3) Licensed physicians, dentists, podiatrists, or optometrists who dispense Class II, Class III, Class IV, and Class V controlled substances directly to patients, but excluding sample medications. For the purposes of this article, sample medications are defined as those drugs labeled as a sample, not for resale under the laws and regulations of the Federal Food and Drug Administration. Controlled substances administered to patients by injection, topical application, suppository administration, or oral administration during the course of treatment are excluded from the reporting requirement.

(c) The manner of reporting controlled substance prescription information shall be in such manner and format as designated in the regulations of the department.

(d) The following data elements shall be used in transmitting controlled substance prescription information:

(1) Name or other identifying designation of the prescribing practitioner.

(2) Date prescription was filled or medications dispensed.

(3) Name of person and full address for whom the prescription was written or to whom the medications were dispensed.

(4) National Drug Code (NDC) of controlled substance dispensed.

(5) Quantity of controlled substance dispensed.

(6) Name or other identifying designation of dispensing pharmacy or practitioner.

(7) Other data elements consistent with standards established by the American Society for Automation in Pharmacy as may be designated by regulations adopted by the department.

(8) Method of payment and third-party payor identification of the controlled substance dispensed.

(e) In addition to any other applicable law or regulation, the failure of a licensed pharmacy or pharmacist or a licensed practitioner to comply with the requirements of this section shall constitute grounds for disciplinary action against the license of the pharmacy, pharmacist, or licensed practitioner by the appropriate licensing board or commission, and the imposition of such penalties as the licensing board or commission may prescribe. The department shall report to the appropriate licensing board, agency, or commission the failure of a licensed pharmacist or a licensed practitioner to comply with the reporting requirements of this section. Any report made by the department to a licensing board, agency, or commission shall be deemed a formal complaint and shall be investigated and appropriate action taken thereon.
Ala. Code § 20-2-142 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-142
Section 20-2-142 Legislative Intent
Status: in_force

It is the intent of the Legislature to remove the merchandising of the “imitation controlled substance” or “lookalike drug” from the street corners, school yards, and campuses of our state, not to interfere with the legitimate distribution of “over the counter” formulations used for the treatment of illness dispensed or sold by licensed practitioners.
Ala. Code § 20-2A-55 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-55
Section 20-2A-55 License Application Procedures
Status: in_force

(a) Beginning September 1, 2022, a person may apply to the commission for a license for an integrated facility or for a license in one of the following independent categories: Cultivator, processor, secure transporter, state testing laboratory, or dispensary. The application shall be made under oath on a form provided by the commission and shall contain information as prescribed by the commission, including, but not limited to, all of the following:

(1) The name, business address, business telephone number, and Social Security number or if applicable, federal tax identification number, of the applicant.

(2) With regard to each business entity that has any ownership interest in the applicant, all of the following:

a. The identity of every individual having an indirect or direct ownership interest in that business entity. For purposes of this paragraph, if the business entity is a trust, the application shall disclose the names and addresses of all trustees and beneficiaries; if a privately held corporation, the names and addresses of all shareholders, officers, and directors; if a publicly held corporation, the names and addresses of all shareholders holding a direct or indirect interest of greater than five percent, officers, and directors; if a partnership or limited liability partnership, the names and addresses of all partners; if a limited partnership or limited liability limited partnership, the names of all partners, both general and limited; or if a limited liability company, the names and addresses of all members and managers.

b.1. The identity of all of the following other entities, if the other entities are directly or indirectly involved in the cannabis industry, including, but not limited to, the cultivation, processing, packaging, labeling, testing, transporting, or sale of cannabis:

(i) Any subsidiary, affiliate, conglomerate, parent, or other entity that shares common ownership, directly or indirectly, with the business entity.

(ii) Any partnership of which the business entity is a partner.

(iii) Any limited liability company of which the business entity is a member or manager.

2. This paragraph shall be construed broadly to ensure the broadest disclosure and greatest transparency reasonably possible.

(3)a. With regard to each individual having any ownership interest in the applicant, the identity of all of the following entities, if the entities are directly or indirectly involved in the cannabis industry, including, but not limited to, the cultivation, processing, packaging, labeling, testing, transporting, or sale of cannabis:

1. Any business entity of which the individual or his or her spouse, parent, or child has any equity interest.

2. Any partnership of which the individual or his or her spouse, parent, or child has any equity interest.

3. Any limited liability company of which the individual or his or her spouse, parent, or child is a member or manager.

b. This subdivision shall be construed broadly to ensure the broadest disclosure and greatest transparency reasonably possible.

(4) Whether an owner, director, board member, or individual with a controlling interest in the applicant has been indicted for, charged with, arrested for, convicted of, pled guilty or nolo contendere to, or forfeited bail concerning any criminal offense under the laws of any jurisdiction, either felony or controlled substance-related misdemeanor, not including traffic violations, regardless of whether the offense has been reversed on appeal or otherwise, including the date, the name and location of the court, arresting agency, and prosecuting agency, the case caption, the docket number, the offense, the disposition, and the location and length of incarceration.

(5) Whether an applicant has ever applied for or has been granted any commercial license or certificate issued by a licensing board or commission in this state or any other jurisdiction that has been denied, restricted, suspended, revoked, or not renewed and a statement describing the facts and circumstances concerning the application, denial, restriction, suspension, revocation, or nonrenewal, including the licensing board or commission, the date each action was taken, and the reason for each action.

(6) Whether an applicant has filed, or been served with, a complaint or other notice filed with any public body, regarding the delinquency in the payment of, or a dispute over the filings concerning the payment of, any tax required under federal, state, or local law, including the amount, type of tax, taxing agency, and time periods involved.

(7) A statement listing the names and titles of all public officials of any unit of government, and the spouses, parents, and children of those public officials, who, directly or indirectly, own any financial interest in, have any beneficial interest in, are the creditors of or hold any debt instrument issued by, or hold or have any interest in any contractual or service relationship with an applicant.

(8) The anticipated or actual number of employees; and projected or actual gross receipts.

(9) Financial information in the manner and form required by rule by the commission.

(10) Records indicating that a majority of ownership is attributable to an individual or individuals with proof of residence in this state for a continuous period of no less than 15 years preceding the application date.

(11) For an applicant seeking an integrated facility license or a cultivator license, records indicating that a majority of ownership is attributable to an individual or individuals, or an entity or entities, with cumulative business experience in the field of commercial horticulture or agronomic production for a period of at least 15 years.

(b) Each owner, shareholder, director, board member, and individual with an economic interest in an applicant shall submit to a state and national criminal background check. The commission shall determine the manner in which fingerprints of the individual shall be submitted to the Alabama State Law Enforcement Agency along with a sufficient fee required to perform the criminal history records check by the agency and by the Federal Bureau of Investigation. The applicant shall submit with its application the individual’s written consent to the criminal history records check.

(c) A false application is cause for the commission to deny a license. The commission shall not consider an incomplete application but, within a reasonable time, shall return the application to the applicant with notification of the deficiency and instructions for submitting a corrected application. Information the commission obtains from the background investigation is exempt from disclosure under the Open Records Act, Article 3 of Chapter 12 of Title 36.

(d) An applicant shall provide written consent to the inspections, examinations, searches, and seizures provided for in subdivision (a)(3) of Section 20-2A-52 and to disclosure to the commission and its agents of otherwise confidential records, including tax records held by any federal, state, or local agency, or credit bureau or financial institution, while applying for or holding a license. Information the commission receives under this subsection is exempt from disclosure under the Open Records Act.

(e) An applicant shall certify that the applicant does not have an economic interest in any other license under this article.

(f) A nonrefundable application fee of two thousand five hundred dollars ($2,500) shall be paid at the time of filing to defray the costs associated with the background investigation conducted by the commission. If the costs of the investigation and processing the application exceed the application fee, the applicant shall pay the additional amount to the commission. All information, records, interviews, reports, statements, memoranda, or other data supplied to or used by the commission in the course of its review or investigation of an application for a license under this article shall be disclosed only in accordance with this article. The information, records, interviews, reports, statements, memoranda, or other data are not admissible as evidence or discoverable in any action of any kind in any court or before any department, agency, board, commission, or authority, except for any action considered necessary by the commission, unless so ordered by a court of competent jurisdiction according to the Rules of Civil Procedure.

(g) If the commission identifies a deficiency in an application, the commission shall provide the applicant with a reasonable period of time, as determined by the commission by rule, but not more than 60 days, to correct the deficiency.
Ala. Code § 20-1-35 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-35
Section 20-1-35 Food Safety Advisory Committee
Status: in_force

There is hereby created the Food Safety Advisory Committee to provide recommendations to the State Board of Agriculture and Industries concerning the promulgation of rules and regulations related to the establishment and definition of class violations under Section 20-1-34, and other definitions required under Section 20-1-34 (d)(5). The committee shall consist of six members to be appointed by the president of each of the following organizations: The Alabama Retail Association, the Alabama Chapter of the National Federation of Independent Businesses, the Business Council of Alabama, the Alabama Grocer’s Association, the Alabama Association of Convenience Stores, and the Alabama Vending Association.
Ala. Code § 20-3-1 — Alabama Code / Title 20 / Chapter 3 / Section 20-3-1
Section 20-3-1 Short Title
Status: in_force

This chapter shall be known and cited as the “John G. Page, Jr., Act.”
Ala. Code § 20-2-93 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-93
Section 20-2-93 Forfeitures; Seizures
Status: in_force

(a) For the purposes of this section only, the following words shall have the following meanings:

(1) CHARGEABLE CRIMINAL OFFENSE. An offense in which property is used or otherwise implicated as property subject to forfeiture under subsection (b). The term includes any act that could be charged as a felony or misdemeanor, regardless of whether a formal criminal prosecution or delinquency proceeding has begun at the time the forfeiture was initiated.

(2) CONTRABAND. All property as described in subsections (t) and (u). The term includes drug paraphernalia, as defined in Section 13A-12-260, and illegal firearms.

(3) FORFEITURE ACTION. A civil action to forfeit property to the state which is initiated by the prosecuting authority in accordance with this section.

(4) INNOCENT OWNER. A bona fide purchaser, lienholder, mortgagee, or other owner, other than a defendant, of property that is subject to forfeiture, including any of the following:

a. A person who has a valid claim, lien, or other interest in the property seized, who did not have knowledge or consent to the conduct that caused the property to be forfeited, seized, or abandoned under subsection (n) and which property is subject to the requirements of subsection (w).

b. A person who has an interest in the property and did not participate in the commission of a crime or delinquent act giving rise to the forfeiture.

(5) INVENTORY. A written, itemized list of all property seized under this section that names all persons to whom the inventory is given at the time of the seizure, as provided in Rule 3.11 of the Alabama Rules of Criminal Procedure.

(6) KNOWLEDGE. An awareness or understanding of information, a fact, or a condition.

(7) PROSECUTING AUTHORITY. The Attorney General, a district attorney, or a designee thereof.

(8) RESPONDENT. Any person asserting a claim or interest in the property subject to the forfeiture action.

(9) SEIZING AGENCY. A state, county, or municipal law enforcement agency or department that seizes property in accordance with this section.

(10) SEIZURE ORDER. A written order issued by a court in connection with a seizure, establishing that probable cause exists to believe that the seizure is valid as described by this section. The term includes, but is not limited to, a search warrant issued pursuant to Article 1, commencing with Section 15-5-1, of Chapter 5 of Title 15.

(b) The following are subject to seizure and forfeiture:

(1) All controlled substances that have been grown, manufactured, distributed, dispensed, or acquired in violation of any law of this state.

(2) All raw materials, products, and equipment of any kind that are used or intended for use in manufacturing, cultivating, growing, compounding, processing, delivering, importing, or exporting any controlled substance in violation of any law of this state.

(3) All monies, negotiable instruments, securities, or other things of value furnished or intended to be furnished by any person in exchange for a controlled substance in violation of any law of this state; all proceeds traceable to such an exchange; and all monies, negotiable instruments, and securities used or intended to be used to facilitate any violation of any law of this state concerning controlled substances.

(4) All property that is used or intended for use as a container for property described in subdivision (1), (2), or (3).

(5) All conveyances, including aircraft, vehicles, or vessels, or agricultural machinery, which are used, or are intended for use, to transport, or in any manner to facilitate the transportation, sale, receipt, possession, or concealment of, any property described in subdivision (1), (2), or (3) .

(6) All books, records, and research products and materials, including formulas, microfilm, tapes, and data, which are used or intended for use in violation of any law of this state concerning controlled substances.

(7) All imitation controlled substances, as defined under the laws of this state.

(8) All real property or fixtures used or intended to be used for the manufacture, cultivation, growth, receipt, storage, handling, distribution, or sale of any controlled substance in violation of any law of this state.

(9) All property of any type whatsoever constituting, or derived from, any proceeds obtained directly, or indirectly, from any violation of any law of this state concerning controlled substances.

(c)(1) All of the following are exempt from seizure and forfeiture under this section:

a. United States currency totaling two hundred fifty dollars ($250) or less.

b. A motor vehicle that is less than five thousand dollars ($5,000) in market value.

(2) For purposes of seizures and forfeitures under subdivision (1), the Attorney General shall advise law enforcement agencies of publications the agencies may use to establish the value of a motor vehicle.

(3) The district attorney for a judicial circuit may increase the minimum dollar amounts provided in subdivision (1) for seizures and forfeitures that occur within the judicial circuit.

(d) Except as provided in subsection (c), property subject to forfeiture under this section may be seized by a seizing agency upon process issued by any court having jurisdiction over the property. Seizure without process may be made under any of the following conditions:

(1) The seizure is incident to an arrest or a search under a search warrant or an inspection under an administrative inspection warrant.

(2) The property subject to seizure has been the subject of a prior judgment in favor of the state in a criminal injunction or forfeiture proceeding based upon this chapter.

(3) The seizing agency has probable cause to believe that the property is directly or indirectly dangerous to health or safety.

(4) The seizing agency has probable cause to believe that the property was used or is intended to be used in violation of this chapter.

(e)(1) In the event of a seizure pursuant to subsection (d), proceedings under subsection (p) shall be instituted promptly. Prior to the commencement of a forfeiture action by the prosecuting authority under this section against property not seized pursuant to a warrant, the seizing agency shall do all of the following:

a. Within seven business days, or an extension of time for good cause shown, after the seizure pursuant to subsection (d), obtain a seizure order from any circuit or district judge in the jurisdiction of the seizure.

b. Within 14 days after obtaining a seizure order under paragraph a., the seizing agency shall present the seizure order and an application for forfeiture, which shall include an inventory, to the prosecuting authority in the jurisdiction for consideration.

(2)a. Upon the issuance of a seizure order pursuant to this subsection, the clerk of the court for the jurisdiction shall establish a circuit civil case number and file the order in that case number, which shall become the case number for the forfeiture action should a prosecuting authority file a forfeiture action pursuant to subsection (g).

b. At the request of the seizing agency, the court may order the filing sealed to protect the confidentiality of any ongoing investigation or witnesses.

(3) If the prosecuting authority has not filed a forfeiture action pursuant to this section after 90 days from the date of the seizure order, the clerk shall notify the judge assigned to the case who may review the case with the prosecuting authority for a possible dismissal due to inaction. Pursuant to an order under this subsection, the property shall be tendered to the owner within 14 business days after the dismissal, unless the property is contraband, in which case the property shall be destroyed at the conclusion of the criminal case.

(4) On motion by the prosecuting authority, property otherwise due to be tendered to the owner pursuant to subdivision (3) or subsection (f) may be retained by the prosecuting authority for the duration of the criminal prosecution only if the prosecuting authority proves, by a preponderance of the evidence, that the seized property is necessary for evidentiary purposes in the criminal prosecution, and that the use of affidavits, photographic evidence, or other admissible evidence is an insufficient means to establish an element of the underlying criminal offense.

(f) A forfeiture action may only be instituted after a finding of probable cause by the prosecuting authority that the seizure is valid. If the prosecuting authority does not find probable cause that the seizure is valid, the property shall be tendered to the owner within 14 business days of the denial, unless the property is contraband, in which case the property shall be destroyed at the conclusion of the criminal case.

(g) Upon compliance with subsection (f), the prosecuting authority may file a forfeiture action in the circuit court under this section within 42 days, or a greater time upon a showing of good cause to the court, from the date of the seizure of the property.

(h) The seizing agency shall provide an inventory to any person in possession of the seized property at the time of the seizure. The inventory shall be prima facie evidence of notice of the seizure to any person served with the inventory at the time of the seizure.

(i)(1) Nothing in this section shall be construed to permit a seizing agency to conduct extrajudicial seizures or forfeitures.

(2) A law enforcement officer may not induce or require a person to waive, for purposes of a seizure or forfeiture action, the person’s interest in property.

(j) On motion of any party, the court may stay the proceedings under this section, including any requirement under the Alabama Rules of Civil Procedure.

(k) Nothing in this section shall prevent the pro tanto dismissal of any party pursuant to the Alabama Rules of Civil Procedure.

(l) An innocent owner may petition the court for a hearing under Section 15-5-63 at any time after seizure of property and before entry of a conviction in the related criminal case.

(m) The state may stipulate that the interest of an innocent owner is exempt from forfeiture upon presentation of proof of the claim. The state shall file the stipulation with the court exercising jurisdiction over the forfeiture action, and the filing of the stipulation shall constitute an admission by the state that the interest is exempt from forfeiture. If a stipulation is submitted, no further claim, answer, or pleading shall be required of the stipulated innocent owner or lienholder, and a judgment shall be entered exempting that interest from forfeiture. An order under this subsection shall waive all court costs.

(n) Convictions or adjudications of chargeable criminal offenses may be considered by the court as prima facie evidence that the property seized is contraband, proceeds, or instrumentalities, and is due to be forfeited. The conviction or adjudication may be proven by the court taking judicial notice or by providing a certified copy of the conviction or adjudication to the court.

(o) All civil forfeiture cases are in rem and all issues shall be tried in the circuit court without the presence of a jury. The state must prove by a preponderance of the evidence the property subject to forfeiture is an instrumentality of, or proceeds derived directly from, a chargeable criminal offense.

(p)(1) The state may file for a default judgment against any party at any time pursuant to the Alabama Rules of Civil Procedure unless the case is stayed under subsection (j). The state may satisfy its burden for a default judgment with testimony taken under oath, or by presenting a sworn to and notarized affidavit.

(2) A respondent shall be deemed to have abandoned the property and any claims to the property, and a default judgment may be entered by the court, upon the occurrence of any of the following:

a. The death of the respondent.

b. The deportation of the respondent.

c. The absconding of the respondent. Violation of bond in the underlying criminal case and the issuance of a failure to appear warrant is prima facie evidence of the respondent’s abandonment of the property.

(q) As part of an order of final judgment, pursuant to a trial or a default judgment hearing, the court shall not condemn and forfeit an instrumentality that is disproportionate to the underlying chargeable criminal offense or offenses that gave rise to the forfeiture action. Among other factors, the court may consider the following in determining whether a seizure is proportional to the underlying chargeable criminal offense or offenses:

(1) The extent to which the property was used in committing the chargeable criminal offense or offenses.

(2) The extent to which the respondent participated in the chargeable criminal offense or offenses.

(3) Any legitimate use of the property seized.

(4) The maximum possible prison sentence for the chargeable criminal offense or offenses.

(5) The maximum possible fines for the chargeable criminal offense or offenses.

(6) Possession of a firearm by the respondent during the chargeable criminal offense or offenses.

(7) The seriousness of the chargeable criminal offense or offenses and its impact on the community, including the duration of the activity and the harm caused.

(r) Property taken or detained under this section shall not be subject to replevin, but is deemed to be in the custody of the seizing agency, subject only to the orders and judgment of the court having jurisdiction over the forfeiture proceedings. When property is seized under this chapter, the seizing agency may do any of the following:

(1) Place the property under seal.

(2) Remove the property to a place designated by the seizing agency.

(3) Require the seizing agency to take custody of the property and remove the property to an appropriate location for disposition in accordance with law.

(4) In the case of real property or fixtures, post notice of the seizure on the property, and file and record notice of the seizure in the probate office.

(s) When property is forfeited under this chapter, the seizing agency may do any of the following:

(1) Retain the property for official use; except for lawful currency of the United States of America which shall be disposed of in the same manner provided for the disposal of proceeds from a sale in subdivision (2) .

(2) Sell that which is not required to be destroyed by law and which is not harmful to the public. The proceeds from the sale authorized by this subdivision shall be used, first, for payment of all proper expenses of the proceedings for forfeiture and sale, including expenses of seizure, maintenance of or custody, advertising, and court costs; and the remaining proceeds from the sale shall be awarded and distributed by the court to the seizing agency or prosecuting authority following a determination of the court of which law enforcement agencies are determined by the court to have been a participant in the investigation resulting in the seizure and litigation. The award and distribution shall be made on the basis of the percentage, as determined by the court, of which respective law enforcement agency or prosecuting authority contributed to the police work or litigation resulting in the seizure and forfeiture. Provided, however, any proceeds from sales authorized by this section awarded by the court to a county or municipal law enforcement agency shall be deposited into the respective county or municipal general fund and made available to the affected law enforcement agency or department upon requisition of the chief law enforcement official of the agency.

(3) Require the seizing agency to take custody of the property and remove it for disposition in accordance with law.

(t) Controlled substances listed in Schedule I that are possessed, transferred, sold, or offered for sale in violation of any law of this state are contraband and shall be seized and summarily forfeited to the state. Controlled substances listed in Schedule I which are seized or come into the possession of the state, the owners of which are unknown, are contraband and shall be summarily forfeited to the state.

(u) Species of plants from which controlled substances in Schedules I and II may be derived, which have been planted or cultivated in violation of any law of this state or of which the owners or cultivators are unknown or which are wild growths, are contraband and may be seized and summarily forfeited to the state.

(v) As used in this subsection, the term “false or secret compartment” means any enclosure that is integrated into or attached to a vehicle, the purpose of which enclosure is to conceal, hide, or prevent discovery of contraband by a law enforcement officer. The term includes, but is not limited to, false, altered, or modified fuel tanks; original factory equipment on a vehicle that has been modified; and any compartment, space, or box that is added or attached to existing compartments, spaces, or boxes of the vehicle. Upon the seizure of a vehicle, the court may infer that the respondent intended to use a false or secret compartment to conceal a controlled substance or other contraband if the vehicle has a false or secret compartment that concealed a controlled substance or other contraband, or evidence is shown of the previous concealment of a controlled substance or other contraband within the false or secret compartment.

(w) An innocent owner’s interest in personal property, real property, or fixtures shall not be forfeited under this section for any act or omission unless the state proves by a preponderance of the evidence that the act or omission was committed or omitted with the knowledge or consent of that owner. An owner’s interest in any type of property other than real property, personal property, and fixtures shall be forfeited under this section unless the owner proves that the act or omission subjecting the property to forfeiture was committed or omitted without the owner’s knowledge or consent. Except as specifically provided to the contrary in this section, the procedures for the condemnation and forfeiture of property seized under this section shall be governed by and shall conform to the procedures set out in Sections 28-4-286 through 28-4-290, except that: (1) The burden of proof and standard of proof shall be as set out in this subsection instead of as set out in the last three lines of Section 28-4-290; and (2) the official filing the complaint shall also serve a copy of it on any person, corporation, or other entity having a perfected security interest in the property that is known to that official or that can be discovered through the exercise of reasonable diligence.

(x)(1) A prosecuting authority or seizing agency may not transfer or offer for adoption property seized under this section to a federal agency for the purpose of forfeiture under the federal Controlled Substances Act, Public Law 91-513 (Oct. 27, 1970), or other federal law, unless the property includes United States currency that exceeds ten thousand dollars ($10,000).

(2) Subdivision (1) only applies to a seizure by a state or local law enforcement agency pursuant to their own authority under this section and without involvement of the federal government. Nothing in subdivision (1) shall be construed to limit state and local agencies from participating in joint task forces with the federal government.

(3) State and local law enforcement agencies may not accept payment of any kind or distribution of forfeiture proceeds from the federal government if the state or local law enforcement agency violates subdivision (1). Any proceeds received as a result of any violation of subdivision (1) shall be directed to the State General Fund.
Ala. Code § 20-2A-7 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-7
Section 20-2A-7 Possession of Marijuana by Registered Qualified Patient; Liability of Registered Certifying Physician; Arrest or Prosecution for Conduct Pursuant to Chapter; Violations of Criminal Law
Status: in_force

(a) A registered qualified patient 19 years of age or older or registered caregiver is not subject to arrest or prosecution for unlawful possession of marijuana if he or she possesses no more than 70 daily dosages of medical cannabis and has a valid medical cannabis card.

(b) A registered certifying physician who acts in good faith compliance with this chapter regarding the dosage established under this chapter and the applicable administrative rules established pursuant to this chapter shall be immune from civil and criminal prosecution and is not subject to arrest, prosecution, or penalty in any manner and may not be denied any right or privilege, including, but not limited to, protection from civil penalty for certifying patients under Section 20-2A-33 or for otherwise stating that, in the physician’s professional opinion, a patient is likely to receive therapeutic or palliative benefit from the medical use of medical cannabis to treat or alleviate the patient’s qualifying medical condition or symptoms associated with the qualifying medical condition, provided that nothing shall prevent the board from disciplining a physician. Nothing in this chapter shall modify, amend, repeal, or supersede any provision of Section 6-5-333, the Alabama Medical Liability Act of 1987, commencing with Section 6-5-540, or the Alabama Medical Liability Act of 1996, commencing with Section 6-5-548, or any amendment to any of these laws or judicial interpretation of these laws.

(c) A licensee or any employee of that licensee is not subject to arrest or prosecution if the person is acting pursuant to this chapter and within the scope of his or her employment.

(d) A hospital, medical facility, assisted living facility, or hospice program where a registered qualified patient is receiving treatment in accordance with this chapter is not subject to arrest, prosecution, or penalty in any manner, or denied any right or privilege solely for providing that treatment.

(e) Mere possession of, or application for, a medical cannabis card does not constitute probable cause or reasonable suspicion, nor shall it be used as the sole basis to support the search of the person, property, or home of the individual possessing or applying for the medical cannabis card. The possession of, or application for, a medical cannabis card does not preclude the existence of probable cause if probable cause exists on other grounds.

(f) Nothing in this chapter shall preclude the Alabama State Law Enforcement Agency or a local law enforcement agency from searching a licensee where there is probable cause to believe that a criminal law has been violated and the search is conducted in conformity with constitutional and state law.
Ala. Code § 20-2-2 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-2
Section 20-2-2 Definitions
Status: in_force

When used in this chapter, the following words and phrases shall have the following meanings, respectively, unless the context clearly indicates otherwise:

(1) ADMINISTER. The direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means, to the body of a patient or research subject by:

a. A practitioner or, in his or her presence, his or her authorized agent.

b. The patient or research subject at the direction and in the presence of the practitioner.

(2) AGENT. An authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. The term does not include a common or contract carrier, public warehouseman, or employee of the carrier or warehouseman.

(3) CERTIFYING BOARDS. The State Board of Medical Examiners, the State Board of Health, the State Board of Pharmacy, the State Board of Dental Examiners, the State Board of Podiatry, and the State Board of Veterinary Medical Examiners.

(4) CONTROLLED SUBSTANCE. A drug, substance, or immediate precursor in Schedules I through V of Article 2 of this chapter.

(5) COUNTERFEIT SUBSTANCE. Substances which, or the container or labeling of which, without authorization, bears the trademark, trade name, or other identifying mark, imprint, number, or device or any likeness thereof of a manufacturer, distributor, or dispenser other than the person who in fact manufactured, distributed, or dispensed the substance.

(6) DELIVER or DELIVERY. The actual, constructive, or attempted transfer from one person to another of a controlled substance, whether or not there is an agency relationship.

(7) DISPENSE. To deliver a controlled substance to an ultimate user or research subject by or pursuant to the lawful order of a practitioner, including the prescribing, administering, packaging, labeling, or compounding necessary to prepare the substance for that delivery.

(8) DISPENSER. A practitioner who dispenses.

(9) DISTRIBUTE. To deliver other than by administering or dispensing a controlled substance.

(10) DISTRIBUTOR. A person who distributes.

(11) DRUG.

a. Substances recognized as drugs in the official United States pharmacopoeia, official homeopathic pharmacopoeia of the United States, or official national formulary or any supplement to any of them.

b. Substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or animals.

c. Substances (other than food) intended to affect the structure or any function of the body of man or animals.

d. Substances intended for use as a component of any article specified in paragraphs a., b., or c. Such term does not include devices or their components, parts, or accessories.

(12) IMMEDIATE PRECURSOR. A substance that the State Board of Pharmacy has found to be and by rule designates as being the principal compound commonly used or produced primarily for use and that is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail, or limit manufacture.

(13) MANUFACTURE. The production, preparation, propagation, compounding, conversion, or processing of a controlled substance, either directly or indirectly, by extraction from substances of natural origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its container; except, that this term does not include the preparation, compounding, packaging, or labeling of a controlled substance by either of the following:

a. A practitioner as an incident to his or her administering or dispensing of a controlled substance in the course of his or her professional practice.

b. A practitioner or his or her authorized agent under his or her supervision for the purpose of or as an incident to research, teaching, or chemical analysis and not for sale.

(14) MARIJUANA. All parts of the plant Cannabis sativa L., whether growing or not, the seeds thereof, the resin extracted from any part of the plant, and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or resin. The term does not include the mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture, or preparation of the mature stalks (except the resin extracted therefrom), fiber, oil or cake, or the sterilized seed of the plant which is incapable of germination. Marijuana does not include hemp as defined in Section 2-8-381.

(15) NARCOTIC DRUG. Any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:

a. Opium and opiate and any salt, compound, derivative, or preparation of opium or opiate.

b. Any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph a., but not including the isoquinoline alkaloids of opium.

c. Opium poppy and poppy straw.

d. Coca leaves and any salt, compound, derivative, or preparation of coca leaves and any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves that do not contain cocaine or ecgonine.

(16) OPIATE. Any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. The term does not include, unless specifically designated as controlled under this section, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). Such term does include its racemic and levorotatory forms.

(17) OPIUM POPPY. The plant of the species Papaver somniferum L., except its seeds.

(18) PERSON. Individual, corporation, government or governmental subdivision or agency, business trust, estate, trust, partnership, or association or any other legal entity.

(19) POPPY STRAW. All parts, except the seeds, of the opium poppy, after mowing.

(20) PRACTITIONER.

a. A physician, dentist, veterinarian, scientific investigator, or other person licensed, registered, or otherwise permitted to distribute, dispense, conduct research with respect to, or to administer a controlled substance in the course of professional practice or research in this state.

b. A pharmacy, hospital, or other institution licensed, registered, or otherwise permitted to distribute, dispense, conduct research with respect to, or to administer a controlled substance in the course of professional practice or research in this state.

(21) PRODUCTION. The manufacture, planting, cultivation, growing, or harvesting of a controlled substance.

(22) STATE. When applied to a part of the United States, the term includes any state, district, commonwealth, territory, insular possession thereof, and any area subject to the legal authority of the United States of America.

(23) ULTIMATE USER. A person who lawfully possesses a controlled substance for his or her own use or for the use of a member of his or her household or for administering to an animal owned by him or her or by a member of his or her household.
Ala. Code § 20-2A-20 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-20
Section 20-2A-20 Creation; Composition; Qualifications; Compensation; Meetings; Officers and Employees
Status: in_force

(a) The Alabama Medical Cannabis Commission is established. The commission shall consist of the following members, with initial members appointed not later than July 1, 2021:

(1) Three members appointed by the Governor, one of whom is a physician licensed to practice medicine in this state; one of whom is a licensed pharmacist; and one of whom has experience in agricultural lending or banking. Initial terms shall be four, three, and two years, respectively.

(2) Three members appointed by the Lieutenant Governor, one of whom is a physician licensed to practice medicine in this state certified in the specialty of pediatrics; one of whom is licensed to practice law in this state who specializes in health law; and one of whom is a biochemist. Initial terms shall be one, four, and three years, respectively.

(3) Two members appointed by the President Pro Tempore of the Senate, one of whom is a physician licensed to practice medicine in this state certified in the specialty of oncology; and one of whom has experience in multiple crop development and agricultural practices. Initial terms shall be two and one years, respectively.

(4) Two members appointed by the Speaker of the House of Representative, one of whom has a background and experience in mental health or substance abuse counselling and treatment; and one of whom has professional experience in agricultural systems management. Initial terms shall be four and three years, respectively.

(5) One member appointed by the Commissioner of Agriculture and Industries who is experienced in agricultural production or agronomic or other horticultural practices. The initial term shall be two years.

(6) One member appointed by the State Health Officer. The initial term shall be four years.

(7) One member appointed by the Attorney General, who shall be a nonvoting advisory member. The initial term shall be three years.

(8) One member appointed by the Secretary of the Alabama State Law Enforcement Agency, who shall be a nonvoting advisory member. The initial term shall be one year.

(b) Each commission member appointed to the commission is subject to confirmation by the Senate during the legislative session in which the appointment is made or, if the appointment is made when the Legislature is not in session, during the next special or regular session. An appointee may serve in the position pending confirmation by the Senate. Each member of the committee shall serve after the expiration of his or her term until his or her successor is appointed.

(c) A member may not be an owner, shareholder, director, board member, or otherwise have an economic interest in an applicant or license issued under Article 4. Any current public official, candidate for public office, current public employee, or registered lobbyist may not serve as a member.

(d) Members must be at least 30 years of age and residents of this state for at least five continuous years immediately preceding their appointment. The appointing officers shall coordinate their appointments so that diversity of gender, race, and geographical areas is reflective of the makeup of this state.

(e) After initial appointments, each member shall serve a term of four years, but may be reappointed for one additional term. If at any time there is a vacancy, a successor member shall be appointed by the respective appointing officer to serve for the remainder of the term. Members may be removed for cause by the appointing authority.

(f) The commission shall elect from the membership one member to serve as chair and one member to serve as vice-chair.

(g) While serving on business of the commission, members who are not public officials or public employees shall be entitled to a per diem of five hundred dollars ($500) per day, as well as actual travel expenses incurred in the performance of duties as a member, as other state employees are paid, when approved by the chair.

(h) The commission shall meet at least six times per year and hold other meetings for any period of time as may be necessary for the commission to transact and perform its official duties and functions. A majority of voting members of the commission shall constitute a quorum for the transaction of any business, or in the performance of any duty, power, or function of the commission, and the concurrence of a majority of those present and voting in any matter within its duties is required for a determination of matters within its jurisdiction. A special meeting may be called by the chair, or upon the written request of two or more members. All members shall be duly notified by the commission director of the time and place of any regular or special meeting at least thirty days in advance of any meeting. Members may participate by telephone, video conference, or by similar communications equipment so that all individuals participating in the meeting may hear each other at the same time. Participating by such means shall constitute presence in person at a meeting for all purposes. The chair shall be responsible for setting and keeping a meeting schedule that ensures the commission meets the requirements of this chapter. A member who misses more than two meetings in one calendar year shall be subject to removal by his or her appointing authority.

(i)(1) The commission may employ a director to serve at the pleasure of the commission. The director’s salary shall be fixed by the commission and shall not be subject to Section 36-6-6. The director shall be at least 30 years of age and have been a citizen and resident of this state for at least five years prior to employment. The director is the chief administrative officer of the commission, and all personnel employed by the commission shall be under the director’s direct supervision. The director shall be solely responsible to the commission for the administration and enforcement of this chapter and responsible for the performance of all duties and functions delegated by the commission.

(2) The director shall maintain all records of the commission and also serve as secretary of the commission. The director shall prepare and keep the minutes of all meetings held by the commission, including a record of all business transacted and decisions rendered by the commission. A copy of the record of the minutes and business transacted and decisions rendered shall be kept on file at the commission’s main office and shall be available for public inspection.

(3) If the director is licensed to practice law in this state, he or she shall act and serve as hearing officer when designated by the commission and shall perform such duties as the regular hearing officer.

(j) The commission may employ an assistant director who shall perform all duties and functions which may be assigned by the director or the commission. The assistant director, if licensed to practice law in this state, may also be designated by the commission to sit, act, and serve as a hearing officer, and when designated as a hearing officer, the assistant director may perform the same duties and functions as the regular hearing officer.

(k) Each member of the commission shall be entitled to the immunity provided by Section 36-1-12.

(l) In any action or suit brought against the members of the commission in their official capacity in a court of competent jurisdiction, to review any decision or order issued by the commission, service of process issued against the commission may be lawfully served or accepted by the director on behalf of the commission as though the members of the commission were personally served with process.

(m) The commission may employ additional officers, including an inspection officer. The director, assistant director, and any other officer or employee shall be reimbursed for actual travel expenses as other state employees are paid, when approved by the chair.

(n) The commission shall retain legal counsel familiar with the requirements of this chapter and medical cannabis licensing and best practices in other states in order to assist the commission and staff with establishing a functional program and achieving compliance with applicable laws.

(o) All employees of the commission shall not be subject to the state Merit System Act.

(p) The commission shall be subject to the Alabama Administrative Procedure Act.
Ala. Code § 20-2B-3 — Alabama Code / Title 20 / Chapter 2B / Section 20-2B-3
Section 20-2B-3 Intercept Order - Grounds
Status: in_force

Orders authorizing, approving, or extending the interception of wire or electronic communications may be granted, subject to this chapter, when the intercept may provide or has provided evidence an individual is committing, has committed, or is about to commit a felony drug offense included in Article 5, commencing with Section 13A-12-201, of Chapter 12, of Title 13A.
Ala. Code § 20-2A-51 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-51
Section 20-2A-51 License Quantities; Operation of Dispensing Sites
Status: in_force

(a) Where the commission is authorized under this article to determine the number of licenses of a specific license category the commission will grant, or increase the number of licenses of a specific license category to grant, the commission shall consider the population of the state, the number of active registered qualified patients, market demand, the unemployment rate, the need for agricultural and other business opportunities in communities, access to health care, infrastructure, and other factors the commission deems relevant in providing the greatest benefits to the residents of this state and taking into account the racial and economic makeup of the state.

(b) The commission shall ensure that at least one-fourth of all licenses, or in the case of Section 20-2A-67, one-fifth of all licenses, are awarded to business entities at least 51 percent of which are owned by members of a minority group or, in the case of a corporation, at least 51 percent of the shares of the corporation are owned by members of a minority group, and are managed and controlled by members of a minority group in its daily operations. For purposes of this subsection, minority group means individuals of African American, Native American, Asian, or Hispanic descent.

(c)(1) Notwithstanding any other provision of this chapter to the contrary, the commission shall not permit a dispensary to operate a dispensing site in any municipality or unincorporated area of a county unless the municipality or county has authorized the operation of dispensing sites within its boundaries, as provided in subdivision (2).

(2) Any county commission, by resolution, may authorize the operation of dispensing sites in the unincorporated areas of the county, and the governing body of any municipality, by ordinance, may authorize the operation of dispensing sites within the corporate limits of the municipality. The county commission or municipal governing body shall notify the commission not more than seven calendar days after adopting the resolution or ordinance.

(3) This subsection does not prohibit a municipality from adopting zoning ordinances restricting the operation of dispensing sites within its corporate limits.
Ala. Code § 20-2-25 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-25
Section 20-2-25 Schedule II - Listing of Controlled Substances
Status: in_force

The controlled substances listed in this section are included in Schedule II:

(1) Any of the following substances, except those narcotic drugs listed in other schedules, whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by combination of extraction and chemical synthesis:

a. Opium and opiate and any salt, compound, derivative, or preparation of opium or opiate.

b. Any salt, compound, isomer, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph a, but not including the isoquinoline alkaloids of opium.

c. Opium poppy and poppy straw.

d. Coca leaves and any salt, compound, derivative, or preparation of coca leaves and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions which do not contain cocaine or ecgonine.

e. Phenibut and any salt, sulfate, free acid, or other preparation of phenibut, and any salt, sulfate, free acid, compound, derivative, precursor, or preparation thereof that is chemically equivalent or identical with phenibut.

(2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:

a. Alphaprodine;

b. Anileridine;

c. Bezitramide;

d. Dihydrocodeine;

e. Diphenoxylate;

f. Fentanyl;

g. Isomethadone;

h. Levomethorphan;

i. Levorphanol;

j. Metazocine;

k. Methadone;

l. Methadone - Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;

m. Moramide - Intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic acid;

n. Pethidine;

o. Pethidine - Intermediate-A, 4-cyano-l-methyl-4-phenylpiperidine;

p. Pethidine - Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;

q. Pethidine - Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;

r. Phenazocine;

s. Piminodine;

t. Racemethorphan;

u. Racemorphan.
Ala. Code § 20-2-66 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-66
Section 20-2-66 Disciplinary Action - Judicial Review
Status: in_force

(a) An assistant to physician adversely affected by an order of the board denying an application for a Qualified Alabama Controlled Substances Registration Certificate or the renewal of a Qualified Alabama Controlled Substances Registration Certificate may obtain judicial review thereof by filing a written petition for review with the Circuit Court of Montgomery County in accordance with Section 41-22-20.

(b) An assistant to physician adversely affected by an order of the board suspending, revoking, or restricting a Qualified Alabama Controlled Substances Registration Certificate, whether or not such suspension, revocation, or restriction is limited; assessing an administrative fine; or denying reinstatement of a Qualified Alabama Controlled Substances Registration Certificate, may obtain judicial review thereof by filing a written petition for review with the Circuit Court of Montgomery County in accordance with Section 41-22-20.

(c) The following procedures shall take precedence over subsection (c) of Section 41-22-20 relating to the issuance of a stay of any order of the board suspending, revoking, or restricting a Qualified Alabama Controlled Substances Registration Certificate. The suspension, revocation, or restriction of a Qualified Alabama Controlled Substances Registration Certificate shall be given immediate effect and no stay or supersedeas shall be granted pending judicial review of a decision by the board to suspend, revoke, or restrict a Qualified Alabama Controlled Substances Registration Certificate unless a reviewing court, upon proof by the party seeking judicial review, finds in writing that the action of the board was taken without statutory authority, was arbitrary or capricious or constituted a gross abuse of discretion.

(d) From the judgment of the circuit court, either the board or the affected party who invoked judicial review may obtain a review of any final judgment of the circuit court under Section 41-22-21. No security shall be required of the board.
Ala. Code § 20-1-74 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-74
Section 20-1-74 Minimum Requirements as to Amounts of Vitamins and Other Ingredients - Flour
Status: in_force

(a) It shall be unlawful for any person to manufacture, mix, compound, sell, trade, or offer for sale or trade for human consumption in this state any flour unless the following vitamins and other ingredients are contained in each pound of such product:

(1) Not less than two milligrams and not more than 2.5 milligrams of vitamin B1 (thiamine);

(2) Not less than 1.2 milligrams and not more than 1.5 milligrams of riboflavin;

(3) Not less than 16 milligrams and not more than 20 milligrams of niacin or niacin amide; and

(4) Not less than 13 milligrams and not more than 16.5 milligrams of iron (Fe).

(b) Such products may contain as optional ingredients not less than 500 milligrams and not more than 625 milligrams of calcium per pound and not less than 250 U.S.P. units and not more than 1,000 U.S.P. units of vitamin D per pound.
Ala. Code § 20-1-34 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-34
Section 20-1-34 Civil Penalties for Violation of Chapter, Etc
Status: in_force

(a) Notwithstanding the existence of any criminal penalty imposed for violations of this chapter and the rules and regulations promulgated hereunder, the department may, after a hearing thereon, impose a civil penalty for violation of this chapter or any rules or regulations promulgated hereunder regarding out-of-date Class A foods, or misbranded or adulterated food, in accordance with the classes provided in subsection (d) below.

(b) Any one offense, and all incidents or violations committed by a person, firm, association, or corporation, arising from the same transaction, shall constitute but one offense.

(c) The board shall by duly adopted rules or regulations, provide maximum penalty amounts to be imposed with regard to out-of-date Class A foods, or misbranded and adulterated food as provided below.

(d) After a public hearing thereon, the board shall, by duly adopted rules or regulations, establish five classes of violations with regard to misbranded and adulterated food.

(1) Class I violations shall be limited to minor or inadvertent violations involving small amounts of out-of-date Class A foods found for which no penalty shall be assessed but a written warning may be given by the department.

(2) Class II violations shall be limited to significant amounts of out-of-date Class A foods or such articles which have been out-of-date for significant periods of time. Penalties for Class II violations shall not exceed one hundred dollars ($100).

(3) Class III violations shall be limited to significant amounts of out-of-date Class A foods or significant amounts of such articles which have been out-of-date for significant periods of time; violations in multiple classes; and/or subsequent Class II violations within one year following a previous Class II violation. Penalties for Class III violations shall not exceed one thousand dollars ($1,000).

(4) Class IV violations shall be limited to food deemed misbranded under Section 20-1-25; large amounts of out-of-date Class A foods or significant amounts of such articles which have been out-of-date for extended periods of time; violations in multiple classes; and/or subsequent Class III violations within one year following a previous Class III violation. Penalties for Class IV violations shall not exceed five thousand dollars ($5,000).

(5) Class V violations shall be limited to food deemed adulterated under Section 20-1-22, and/or subsequent Class IV violations. Provided, however, to sustain a penalty under this subdivision, with regard to out-of-date Class A foods, there must be a showing by a preponderance of evidence that there were large amounts of out-of-date Class A foods found, or that significant amounts of such articles found had been out-of-date for extended periods of time and that the violations were willful, knowing, or intentional. Penalties for Class V violations shall not exceed a maximum penalty amount of ten thousand dollars ($10,000) and may include the revocation of the person’s food safety permit.

(e) The board shall by duly adopted rules or regulations establish a list of items included in the definition of “potentially hazardous foods.” The board shall also by duly adopted rules or regulations provide for detailed definitions of the above referenced classes of violations which shall include definitions of the terms “minor or inadvertent violations,” “small amounts,” “significant amounts,” “significant periods of time,” “large amounts,” “extended periods of time,” and similar terms.

(f) The failure of any person, firm, association, or corporation to pay an assessed penalty in a timely manner, as defined by duly adopted rules or regulations of the board, shall constitute grounds for the revocation of any food safety permit issued under this chapter. Such revocation shall be made pursuant to a due process hearing before a hearing officer and in the same manner as provided for suspension and revocation of permits under the provisions of Section 20-1-33(e).

(g) Under this section, appeals from an assessment of any penalty levied shall be made in a timely manner in accordance with the rules for contested cases under the Alabama Administrative Procedure Act, Section 41-22-12, et seq. Judicial review may be taken in circuit court in accordance with the provisions of the Alabama Administrative Procedure Act, Section 41-22-20, et seq.

The foregoing notwithstanding, in cases involving Class IV or Class V violations or permit revocations thereunder, judicial review shall be by trial de novo in circuit court in accordance with the provisions of the Alabama Administrative Procedure Act, Section 41-22-20 (j).

(h) All moneys received from the assessment of any penalty under this section shall accrue to the General Fund and shall be appropriated by the Legislature as provided by law.
Ala. Code § 20-2-117 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-117
Section 20-2-117 Contracts for Receipt of Cannabis; Board of Medical Examiners to Promulgate Guidelines, Rules and Regulations
Status: in_force

The State Board of Medical Examiners may apply to contract with the National Institute of Drug Abuse for receipt of cannabis pursuant to the regulations promulgated by the National Institute on Drug Abuse, the Food and Drug Administration, and the Drug Enforcement Administration. The board may formulate and promulgate such guidelines as are necessary for dispensing cannabis consistent with the public health and safety and under strictly controlled circumstances. The board further may establish the rules and regulations requiring accurate reporting and accountability by each practitioner to the board and any federal agency as required by law.
Ala. Code § 20-3-3 — Alabama Code / Title 20 / Chapter 3 / Section 20-3-3
Section 20-3-3 Transfer of Legend Drugs to Charitable Clinic
Status: in_force

(a)(1) Legend drugs, except controlled substances, dispensed to a patient in a hospital, nursing facility, assisted living facility, or specialty care assisted living facility may be donated and transferred pursuant to this section to a charitable clinic to be used by charitable patients free of charge when all of the following conditions are met:

a. The drugs are no longer needed by the original patient.

b. The drugs have been maintained in accordance with United States Pharmacopoeia and National Formulary storage requirements.

c. The drugs were dispensed by unit dose or an individually sealed dose.

d. The drugs have not expired.

(2) Legend drugs, except controlled substances, dispensed to a patient cared for by a hospice care program may be donated and transferred pursuant to this section to a charitable clinic to be used by charitable patients free of charge when all of the following conditions are met:

a. The drugs are no longer needed by the original patient.

b. The drugs were dispensed by unit dose or bulk packaging.

c. The drugs have not expired.

(b) The physician or licensed health care professional of the charitable clinic shall be responsible for determining the suitability of the product for reuse. No product where integrity may not be assured shall be used by the physician at the charitable clinic. A legend drug shall be assigned the expiration date stated on the package.

(c) Pursuant to a voluntary agreement between a nursing home, hospital, specialty care assisted living facility, or hospice care program and a charitable clinic, legend drugs may be transferred pursuant to this chapter from the nursing home, hospital, assisted living facility, or specialty care assisted living facility or from the residence of a hospice patient to the charitable clinic if the following procedures are satisfied:

(1) The legend drugs shall be physically transferred to a person authorized in writing to pick up the drugs for the charitable clinic.

(2) The file of a patient at the nursing home, hospital, assisted living facility, or specialty care assisted living facility or the file of a patient cared for by a hospice care program shall document his or her consent, or in the case of the death of a patient the patient’s family’s consent, for the donation.

(3) The patient’s name, prescription number, and any other identifying marks shall be obliterated from the drug container prior to removal from the nursing home, hospital, assisted living facility, or specialty care assisted living facility or the residence of a hospice patient.

(4) The name, strength, and expiration date of the legend drug shall remain on the medication package label.

(5) An inventory list of the legend drugs shall accompany the drugs being transferred, which list, at a minimum, shall contain for each drug the medication name, strength, expiration date, and quantity.

(6) Within one week after an inventoried list of legend drugs is made available, the drugs shall be picked up by a charitable clinic or the drugs shall be destroyed.

(d) A licensed nursing home, hospital, specialty care assisted living facility, assisted living facility, or hospice care program, or an owner, operator, employee, or agent of a licensee, shall not be liable for civil damages or for any criminal liability as a result of any acts or omissions in transferring any drugs pursuant to this section unless the act or omission was the result of willful misconduct.

(e) No pharmaceutical manufacturer shall be liable for any claim or injury arising due to a transfer of any legend drug pursuant to this chapter, including, but not limited to, liability for failure to transfer or communicate product or consumer information or the expiration date regarding the transferred drug.

(f) The State Board of Health may make rules and regulations to carry out the provisions and purposes of this section.

(g) All legend drugs distributed under the authority of this chapter shall be dispensed to a patient, resident, or other user only on the order of a licensed physician or other legally authorized licensed medical practitioner.
Ala. Code § 20-2-212 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-212
Section 20-2-212 Controlled Substances Prescription Database Program; Powers and Duties of Department; Trust Fund; Advisory Committee; Review Committee
Status: in_force

(a) The department may establish, create, and maintain a controlled substances prescription database program. In order to carry out its responsibilities under this article, the department is granted the following powers and authority:

(1) To adopt regulations, in accordance with the Alabama Administrative Procedure Act, governing the establishment and operation of a controlled substances prescription database program.

(2) To receive and to expend for the purposes stated in this article funds in the form of grants, donations, federal matching funds, interagency transfers, and appropriated funds designated for the development, implementation, operation, and maintenance of the controlled substances prescription database. The funds received pursuant to this subdivision shall be deposited in a new fund that is established as a separate special revolving trust fund in the State Treasury to be known as the Alabama State Controlled Substance Database Trust Fund. No monies shall be withdrawn or expended from the fund for any purpose unless the monies have been appropriated by the Legislature and allocated pursuant to this article. Any monies appropriated shall be budgeted and allocated pursuant to the Budget Management Act in accordance with Article 4 (commencing with Section 41-4-80) of Chapter 4 of Title 41, and only in the amounts provided by the Legislature in the general appropriations act or other appropriations act.

(3) To enter into one or more contracts with the State Board of Pharmacy for the performance of designated operational functions for the controlled substances prescription database, including, but not limited to, the receipt, collection, input, and transmission of controlled substances prescription data and such other operational functions as the department may elect.

(4) To create a Controlled Substances Prescription Database Advisory Committee and an Information Release Review Committee.

(b)(1) The mission of the Controlled Substance Prescription Database Advisory Committee is to consult with and advise the State Health Officer on matters related to the establishment, maintenance, and operation of the database, access to the database information, how access is to be regulated, and security of information contained in the database.

(2) The advisory committee shall consist of the following:

a. One representative designated by the Medical Association of the State of Alabama.

b. One representative designated by the Alabama Dental Association.

c. One representative designated by the Alabama Pharmacy Association.

d. One representative designated by the Alabama Veterinary Medicine Association.

e. The director of the controlled substances prescription database program in the department.

f. One representative designated by the Alabama Hospital Association.

g. The Executive Director of the Alabama State Board of Pharmacy, or his or her designee.

h. The Executive Director of the Board of Medical Examiners, or his or her designee.

i. One representative designated by the Alabama Optometric Association.

j. One representative from each of the certifying boards established under the Alabama Uniform Controlled Substances Act.

k. One representative designated by the Alabama Medicaid Agency.

l. One representative designated by the Alabama Podiatry Association.

m. One representative designated by the Alabama Department of Mental Health.

n. The Attorney General, or his or her designee.

(3) If a member of the Controlled Substances Prescription Database Advisory Committee is unable to attend a meeting, the organization which appointed that member may designate one of its employees or agents as a proxy. A proxy may participate in all deliberations of the committee and vote on all questions considered by the advisory committee. Designations of a proxy must be in writing, must specify by name the individual who will serve as proxy, and must specify the date of the meeting at which the proxy is authorized to serve. There must be a separate written proxy designation for each meeting at which a proxy will serve.

(4) The appointing authorities of the committee shall coordinate their appointments to assure the committee membership is inclusive and reflects the racial, gender, geographic, urban/rural, and economic diversity of the state.

(5) Members of the Controlled Substances Prescription Database Advisory Committee may participate in a meeting by means of conference telephone, video conference, or similar communications equipment by means of which all persons participating in the meeting may hear each other at the same time. Participation by such means shall constitute presence in person at a meeting for all purposes, including the establishment of a quorum. Telephone or video conference or similar communications equipment shall also allow members of the public the opportunity to simultaneously listen to or observe the meetings.

(c)(1) The mission of the Information Release Review Committee is to review statistical, research, or educational requests for information, departmental research requests, or department requests regarding publication of information from the controlled substances database.

(2) The review committee shall consist of one licensed practitioner appointed by the State Board of Medical Examiners, one licensed practitioner appointed by the State Board of Dental Examiners, one licensed pharmacist appointed by the State Board of Pharmacy, one representative experienced in medical informatics or clinical research appointed by the State Health Officer, and one representative experienced in medical informatics or clinical research appointed by the Attorney General.

(3) Members of the Information Release Review Committee may receive electronically from the department statistical, research, or educational requests for information, departmental research requests, or department requests regarding publication of information and may respond electronically in order to provide their approval or disapproval of those requests.
Ala. Code § 20-2A-66 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-66
Section 20-2A-66 State Testing Laboratory Licensing
Status: in_force

(a) A state testing laboratory license authorizes the licensee to possess and test cannabis and medical cannabis products cultivated or processed at licensed facilities.

(b) The commission, by rule, shall establish protocols for product testing by a licensed state testing laboratory, which shall be conducted during cultivation, processing, and dispensing to ensure that all dispensed medical cannabis is consistently high grade and maintains a consistency with less than 0.5 percent variability among batches of the same product. The protocols for testing shall include the following, as well as a determination of corresponding tolerance limits:

(1) Cannabinoid content and potency, including, but not limited to, all of the following:

a. Total THC (THC+THCA).

b. Total CBD (CBD+CBDA).

c. THC/CBD ratio, if applicable.

d. Percent of THC relative to original plant material (w/w).

(2) Terpene profiles.

(3) Heavy metals.

(4) Chemical contamination, such as residual solvents remaining after extraction and concentration.

(5) Microbials, including pathogenic microbials.

(6) Mycotoxins.

(7) Residual insecticides, fungicides, herbicides, and growth regulators used during cultivation.

(8) Residual solvents.

(c) A state testing laboratory license authorizes the licensee to do all of the following without using a secure transporter:

(1) Take cannabis or medical cannabis from, test cannabis or medical cannabis for, and return cannabis or medical cannabis to only a respective licensed facility.

(2) Collect a random sample of cannabis or medical cannabis at the premises of a cultivator, processor, or dispensary for testing.

(d) The licensee shall be accredited and shown to meet the requirements for a testing laboratory in international standard ISO/IEC 17025, with the licensee’s scope of accreditation demonstrating testing capabilities in the categories of cannabinoids, pesticides, toxins, metals, and microbiological bacteria.

(e) To be eligible for a state testing laboratory license, the applicant and each investor with any interest in the applicant must not have an interest in any licensed cultivator, secure transporter, processor, or dispensary.

(f) The licensee shall comply with all of the following:

(1) Perform tests to certify that cannabis and medical cannabis is reasonably free of heavy metals, chemical contamination, residual pesticides and growth inhibitors, and residual solvents.

(2) Use validated test methods to determine delta-9-tetrahydrocannabinol, tetrahydrocannabinolic acid, cannabidiol, and cannabidiolic acid levels.

(3) Perform tests that determine whether cannabis and medical cannabis comply with the standards the commission establishes for microbial and mycotoxin contents.

(4) Perform other tests necessary to determine compliance with any other good manufacturing practices as prescribed in rules.

(5) Have a secured laboratory space that cannot be accessed by the general public.

(6) Retain and employ at least one staff member with a relevant advanced degree in a medical or laboratory science.
Ala. Code § 20-1-2 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-2
Section 20-1-2 Adoption of Rules and Regulations
Status: in_force

The State Board of Agriculture and Industries is authorized to adopt and promulgate such rules and regulations as are reasonable and necessary to the accomplishment of the purposes of this chapter and to make effective its provisions.
Ala. Code § 20-1-112 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-112
Section 20-1-112 Changes of Specifications as to Addition of Vitamins to Oleomargarine by State Board of Agriculture and Industries
Status: in_force

The State Board of Agriculture and Industries is empowered with the authority and is directed to change or add to the specifications for ingredients and the amounts thereof required to conform to any changes in 21 Code of Federal Regulations, Part 45, concerning the addition of vitamins to oleomargarine.
Ala. Code § 20-2-188 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-188
Section 20-2-188 Exceptions to Requirements for Sale or Transfer of Chemicals, and to Licensing Requirements
Status: in_force

(a) The provisions of this article shall not apply to the sale or transfer of products which include a listed precursor chemical if the product may be sold lawfully with a prescription or over the counter without a prescription under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.), or under a rule adopted pursuant to that act.

(b) Notwithstanding any other provision of this article, no person shall be required to obtain a listed precursor license or permit for the sale, receipt, transfer, manufacture, or possession of a listed precursor chemical when:

(1) Such person is a duly licensed physician, dentist, veterinarian, podiatrist, or pharmacist, when the sale, receipt, transfer, manufacture, or possession of such listed precursor chemical is a transaction otherwise lawfully authorized;

(2) A domestic lawful distribution in the usual course of business between agents or employees of a single regulated person;

(3) A delivery of a listed precursor chemical to or by a common or contract carrier for carriage in the lawful and usual course of the business of the common or contract carrier or to or by a warehouseman for storage in the lawful and usual course of the business of the warehouseman.
Ala. Code § 20-1-36 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-36
Section 20-1-36 Donations to Exempt Organizations
Status: in_force

Nothing in Act 2000-320 shall prohibit the donation of any food by any food sales establishment, food manufacturer, or food distributor to an organization defined under Section 501(c)(3) of the Internal Revenue Code of 1986, as amended. Nor shall the provisions of Act 2000-320 prohibit the sale, donation, or other distribution of any food by a Section 501(c)(3) organization to a 501(c) organization. Any provision of law to the contrary notwithstanding, the term food as used in this section shall not include an out-of-date Class A food or an adulterated food as defined by law.
Ala. Code § 20-1-75 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-75
Section 20-1-75 Minimum Requirements as to Amounts of Vitamins and Other Ingredients - Bread
Status: in_force

(a) It shall be unlawful for any person to manufacture, bake, sell, or offer for sale or to receive in interstate shipment for sale for human consumption in this state any bread (as defined in subdivision (1) of Section 20-1-71) unless the following vitamins and other ingredients are contained in each pound of such bread:

(1) Not less than 1.10 milligrams and not more than 1.80 milligrams of vitamin B1 (thiamine);

(2) Not less than 10.0 milligrams and not more than 15.0 milligrams of niacin or niacin amide;

(3) Not less than 0.7 milligrams and not more than 1.60 milligrams of riboflavin; and

(4) Not less than eight milligrams and not more than 12.5 milligrams of iron (Fe).

(b) Such bread may contain as optional ingredients not less than 300 milligrams and not more than 800 milligrams of calcium and/or not less than 150 U.S.P. units and not more than 750 U.S.P. units of vitamin D per pound.
Ala. Code § 20-1-25 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-25
Section 20-1-25 When Articles Deemed Misbranded Generally - Food
Status: in_force

An article of food shall be deemed misbranded in the following cases:

(1) If it is offered for sale under the name of another article;

(2) If it is labeled or branded so as to deceive or mislead the purchaser, or purports to be a foreign product when not so or if the contents of the package as originally put up shall have been removed in whole or in part and other contents shall have been placed in such package;

(3) If, in package form, the name of the article together with the quantity of the contents in terms of weight, measure, or numerical count and the name and principal address of the manufacturer or other person responsible for placing the article on the market are not plainly and conspicuously marked on the outside of the package;

(4) If, in package form, the package is not filled with the food it purports to contain within the limits of tolerance fixed by the State Board of Agriculture and Industries, irrespective of whether the quantity of the contents is plainly and conspicuously marked on the outside of the package in terms of weight, measure, or numerical count;

(5) If the package containing it or its label shall bear any statement, design, or device regarding the ingredients or the substances contained therein, which statement, design, or device shall be false or misleading in any particular;

(6) If, in bulk, it is colored so as to deceive or mislead the purchaser;

(7) If it is offered for sale under false representations;

(8) If it is an imitation of another article and is not marked with the word “imitation,” followed, without intervening descriptive matter, by a list of the ingredients contained therein;

(9) If it is a compound for which no standard of purity or quality has been established, and it is not labeled with the word “compound” followed, without intervening descriptive matter, by a list of the ingredients; provided, that in the case of a compound which may be now or from time to time hereafter known as an article of food under its own distinctive name and which is not an imitation of or offered for sale under the name of another article, it shall not be deemed to be misbranded if the name of the article is accompanied on the same label or brand with a statement of the place where such article was manufactured or produced; or

(10) If the package, label, or brand fails to give the ingredients or substances by their common names.
Ala. Code § 20-2A-5 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-5
Section 20-2A-5 Data Security
Status: in_force

All data related to the implementation of this chapter, including, but not limited to, application forms, licensing information, physician certifications, registration of qualified patients and designated caregivers, compliance, and the status of cannabis research programs must be maintained in a secure system developed or procured by the commission. Data may not be sold, and patient information shall remain confidential, except as otherwise permitted pursuant to this chapter, and may not be transferred or sold.
Ala. Code § 20-2-63 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-63
Section 20-2-63 Prescriptive Authority of a Certified Assistant to Physician
Status: in_force

(a) Upon receipt of a Qualified Alabama Controlled Substances Registration Certificate and a valid registration number issued by the United States Drug Enforcement Administration, an assistant to physician may prescribe, administer, authorize for administration, or dispense only those controlled substances listed in Schedules III, IV, and V of Article 2 of Chapter 2 of this title in accordance with rules adopted by the board and any protocols, formularies, and medical regimens established by the board for regulation of a QACSC.

(b) An assistant to physician shall not utilize his or her QACSC for the purchasing, obtaining, maintaining, or ordering of any stock supply or inventory of any controlled substance in any form.

(c) An assistant to physician authorized to prescribe, administer, or dispense controlled substances in accordance with this article shall not prescribe, administer, or dispense any controlled substance to his or her own self, spouse, child, or parent.
Ala. Code § 20-1-110 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-110
Section 20-1-110 Short Title
Status: in_force

This article shall be known as the Oleomargarine Fortification Act.
Ala. Code § 20-2-24 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-24
Section 20-2-24 Schedule II - Standards for Compilation
Status: in_force

The State Board of Health shall place a substance in Schedule II if it finds that:

(1) The substance has high potential for abuse;

(2) The substance has currently accepted medical use in treatment in the United States or currently accepted medical use with severe restrictions; and

(3) The abuse of the substance may lead to severe psychic or physical dependence.
Ala. Code § 20-2A-58 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-58
Section 20-2A-58 Exclusivity of License; Transfer Request
Status: in_force

(a) Each license is exclusive to the licensee. A license, and any interest in or rights under a license, and any ownership interest or other beneficial interest in a licensed entity, may not be sold, transferred, assigned, conveyed, or otherwise disposed of in any manner, in whole or in part, voluntarily or involuntarily, directly or indirectly, except upon application to and approval of the commission.

(b) A nonrefundable application fee of two thousand five hundred dollars ($2,500) shall be paid to the commission at the time of filing any transfer request under subsection (a).

(c) The attempted transfer, sale, or other conveyance of an interest or right in a license, or transfer of an ownership interest or other beneficial interest in a licensed entity, without the approval of the commission, shall be grounds for suspension or revocation of the license or for other sanction considered appropriate by the commission.
Ala. Code § 20-2A-8 — Alabama Code / Title 20 / Chapter 2A / Section 20-2A-8
Section 20-2A-8 Diversion of Medical Cannabis or Medical Cannabis Products; Prohibited Conduct
Status: in_force

(a)(1) An individual may not distribute, possess, manufacture, or use medical cannabis or a medical cannabis product that has been diverted from a registered qualified patient, a registered caregiver, or a licensed cultivator, processor, secure transporter, dispensary, or a state testing laboratory.

(2) An individual who violates this section is guilty of a Class B felony.

(3) The penalty under this section is in addition to any penalties that a person may be subject to for manufacture, possession, or distribution of marijuana under Title 13A.

(b) This chapter does not permit any individual to engage in, and does not prevent the imposition of any civil, criminal, or other penalty for engaging in any of the following conduct:

(1) Undertaking any task under the influence of cannabis, when doing so would constitute negligence, professional malpractice, or professional misconduct, or violation of law.

(2) Possessing or using medical cannabis on any property of a K-12 school or day care or child care facility, in any correctional facility, or in a vehicle unless the medical cannabis is in its original package and is sealed and reasonably inaccessible while the vehicle is moving.
Ala. Code § 20-1-22 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-22
Section 20-1-22 When Articles Deemed Adulterated - Food Generally
Status: in_force

An article shall be deemed adulterated in the case of food:

(1) If any substance has been mixed and packed with it so as to reduce or lower or injuriously affect its quality or strength;

(2) If any substance has been substituted wholly or in part for the article;

(3) If any valuable constituent of the article has been wholly or in part abstracted;

(4) If it is mixed, colored, powdered, coated, stained, or otherwise treated in a manner whereby damage or inferiority is concealed or in a manner whereby the appearance of said article is improved; provided, that this subdivision shall not apply to the precoloring or processing of fruits where such precoloring or processing does not conceal damage or inferiority;

(5) If it contains any poisonous or deleterious ingredient which may render such article injurious to health;

(6) If it consists in whole or in part of a filthy, decomposed, or putrid animal or vegetable substance or any portion of an animal unfit for food, whether manufactured or not, or if it is the product of a diseased animal, or of one that has died otherwise than by slaughter;

(7) If, in the course of its preparation or manufacture, an ingredient of inferior food value has been substituted in whole or in part for an ingredient of greater food value; or

(8) If it does not conform to the standard of purity or quality established for the article; provided, that when in the preparation of food products for shipment they are preserved by an external application applied in such a manner that the preservative is necessarily removed mechanically or by maceration in water or otherwise, and directions for the removal of said preservative shall be printed on the covering of the package, the provisions of this division shall be construed as applying only when said products are ready for consumption.
Ala. Code § 20-1-134 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-134
Section 20-1-134 Requirements as to Sale Generally
Status: in_force

Mellorine shall be sold only in factory filled packages of pints, quarts, or half gallon capacity (liquid measure) and shall not be sold or served in novelties, cake cones, dishes, milk shakes, milk drinks, malt drinks, sodas, sundaes, or other similar items customarily served at soda fountains and eating establishments. The sale of mellorine in any manner other than as provided in this section is prohibited.
Ala. Code § 20-2-116 — Alabama Code / Title 20 / Chapter 2 / Section 20-2-116
Section 20-2-116 Certification in Subspecialty of Oncology Required; Certification by State Board of Medical Examiners; Recertification
Status: in_force

Only physicians in the practice of medicine as prescribed in Section 20-2-115 and specifically certified by the State Board of Medical Examiners to dispense cannabis under the provisions of this article, shall be practitioners hereunder. Each practitioner shall make application for recertification every three years.
Ala. Code § 20-1-21 — Alabama Code / Title 20 / Chapter 1 / Section 20-1-21
Section 20-1-21 Purpose of Division; Standards; Construction of Chapter
Status: in_force

(a) The purpose of this division is to prevent the manufacture, possession, sale, or delivery of out-of-date Class A foods and adulterated or misbranded food and drugs.

(b) The State Board of Agriculture and Industries shall have the power and authority and it shall be its duty to fix the standards of purity for all food and drug products which shall be, so far as practical, in accordance with the standards promulgated by the federal government through its duly authorized agents.

(c) The provisions of this chapter regarding the sale of any article shall be considered to include the manufacture, production, packaging, offer, offer for transportation, transportation, exposure, possession, and holding of any such article and the supplying or applying of any such article in the conduct of any food establishment.